WO2011111876A1 - Clearing reagent for biological material, and use thereof - Google Patents
Clearing reagent for biological material, and use thereof Download PDFInfo
- Publication number
- WO2011111876A1 WO2011111876A1 PCT/JP2011/056502 JP2011056502W WO2011111876A1 WO 2011111876 A1 WO2011111876 A1 WO 2011111876A1 JP 2011056502 W JP2011056502 W JP 2011056502W WO 2011111876 A1 WO2011111876 A1 WO 2011111876A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- clearing
- biological material
- reagent
- clearing reagent
- treatment
- Prior art date
Links
- 239000012620 biological material Substances 0.000 title claims abstract description 199
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 176
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000004202 carbamide Substances 0.000 claims abstract description 60
- 150000003672 ureas Chemical class 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 148
- 238000000034 method Methods 0.000 claims description 44
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 229920002521 macromolecule Polymers 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 26
- 239000004094 surface-active agent Substances 0.000 claims description 23
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 12
- 229920001917 Ficoll Polymers 0.000 claims description 11
- 239000002736 nonionic surfactant Substances 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 239000012266 salt solution Substances 0.000 claims description 9
- 239000012466 permeate Substances 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229960003511 macrogol Drugs 0.000 claims description 3
- 229920002113 octoxynol Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 210000001320 hippocampus Anatomy 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 29
- 239000002904 solvent Substances 0.000 description 28
- 108091006047 fluorescent proteins Proteins 0.000 description 23
- 102000034287 fluorescent proteins Human genes 0.000 description 22
- 210000004720 cerebrum Anatomy 0.000 description 21
- 210000001947 dentate gyrus Anatomy 0.000 description 17
- 210000003710 cerebral cortex Anatomy 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 125000001183 hydrocarbyl group Chemical group 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 210000005155 neural progenitor cell Anatomy 0.000 description 9
- 210000004885 white matter Anatomy 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 210000003754 fetus Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- -1 polyoxyethylene octylphenyl ether Polymers 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000002834 transmittance Methods 0.000 description 5
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 229960002903 benzyl benzoate Drugs 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 210000000877 corpus callosum Anatomy 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000545067 Venus Species 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 108010021843 fluorescent protein 583 Proteins 0.000 description 2
- 210000001308 heart ventricle Anatomy 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000012112 Alexa Fluor 633 Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100457021 Caenorhabditis elegans mag-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 240000000244 Crotalaria pallida Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100067996 Mus musculus Gbp1 gene Proteins 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000036366 Sensation of pressure Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000010869 super-resolution microscopy Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
Definitions
- the present invention relates to a clearing reagent for making a biological material transparent, and use thereof.
- a pretreatment (a clearing treatment for making a subj ect transparent) using a clearing reagent is performed .
- Patent Literature U.S. Patent No. 6472216 (Date of patent: October 29, 2002)
- the Focus Clear solution which contains dimethyl sulfoxide (DMSO) and/or the like as an active component for making a subject transparent, is difficult to be used on living tissues. Therefore, subjects to which the Focus Clear solution can be applied are limited largely to fixed samples.
- DMSO dimethyl sulfoxide
- the Focus Clear solution has a quite complicated composition, whereby preparation thereof is complicated, and its cost is very high. Furthermore, although it is suggested that the Focus Clear solution would allow an observation using a fluorescent protein, the Focus Clear solution shrinks nervous tissues and does not sufficiently clear turbidity of nervous tissue at deep area. Meanwhile , the tissue clearing method of Dodt et al. essentially requires use of a large amount of an organic solvent in a step for making a subj ect transparent. Therefore , this method is also difficult to be used on living tissues, and subj ects to which this method can be applied are limited largely to fixed samples.
- the tissue clearing method essentially requires use of a large amount of an organic solvent, this method damages almost all fluorescent proteins . As such, with this method , it is difficult to perform a tissue observation using a fluorescent protein.
- tissue clearing method described above involve s dehydration of a tissue subj ected to a clearing treatment, which is due to the nature of their compositions .
- this process causes irreversible shrinkage of the tissue .
- the present invention was made in order to solve the foregoing problems , and an obj ect of the present invention is to provide : a novel clearing agent for making a biological material transparent which clearing agent contains, as an active component, a component having a higher bio-affinity; and use thereof.
- the inventors of the present invention made diligent studies to reach a new finding that, among components having excellent bio- affinities , urea has ability to make a biological material transparent. Based on this, the present inventors arrived at the present invention .
- a clearing reagent for making a biological material transparent includes, as an active component, at least one compound selected from the group consisting of urea and urea derivatives, the clearing reagent being a solution .
- the present invention also provides a system for a clearing treatment for making a biological material transparent, including: any of the above clearing reagents ; and a biological material which has been isolated, the clearing reagent having permeated into the biological material in order to make the biological material transparent.
- a method according to the present invention for making a biological material transparent includes the step of: causing any of the above clearing reagents to permeate into a biological material which has been isolated, in order that the biological material is made transparent.
- a method according to the present invention for recovering a biological material having been made transparent by a clearing treatment includes the step of: causing an equilibrium salt solution to permeate into a biological material having been made transparent according to the above method , in order that the biological material is brought back to a state that the biological material had before the clearing treatment.
- the present invention also provides a kit for a clearing treatment for making a biological material transparent, including any of the above clearing reagents .
- the present invention provides : a novel clearing reagent for making a biological material transparent which clearing reagent contains , as an active component, a component having a higher bio-affinity; and use thereof.
- Fig. 1 is a view showing a mouse hippocampus treated with a clearing reagent according to the present invention for making a biological material transparent.
- Fig. 2 is a view showing a mouse hippocampus treated with a clearing reagent according to the present invention for making a biological material transparent.
- Fig. 3 related to further another example of the pre sent invention, is a view showing the whole of a mouse cerebrum treated with a clearing reagent according to the present invention for making a biological material transparent.
- Fig. 4 related to still further another example of the present invention, is a graph illustrating a relationship between (i) a clearing reagent according to the present invention for making a biological material transparent and (ii) swelling of a biological material treated with the clearing reagent.
- Fig. 5 is a view showing the whole of a mouse cerebrum treated with a clearing reagent according to the present invention for making a biological material transparent.
- Fig. 6 is a graph showing the result of light transmittance measurement of mouse brain slices having been treated with clearing reagents according to the present invention for making a biological material transparent.
- Fig. 7 is a view showing a mouse fetal treated with a clearing reagent according to the pre sent invention for making a biological material transparent.
- Fig. 8 related to a further additional example of the present invention, is a view showing the result of an observation of the neural progenitor cells in a mouse hippocampus treated with a clearing reagent according to the present invention for making a biological material transparent.
- Fig. 9 is a view for comparison between mouse cerebrum sample s treated with a clearing reagent according to the present invention for making a biological material transparent, or with a conventional technique (BABB method) .
- Fig. 10 is a view for comparison between the results of HeLa cells having various fluorescent proteins expre ssed therein , the HeLa cells having been treated with a clearing reagent according to the present invention for making a biological material transparent or with a conventional technique (BABB method) .
- Fig. 1 1 is a view showing the result of an observation of a cerebral cortex having neural progenitor cells transplanted thereto , which cerebral cortex was treated with a clearing reagent according to the present invention for making a biological material transparent.
- Fig. 12 is a view showing the results of immunostaining on (i) biological materials before a clearing treatment with a clearing reagent according to the present invention for making a biological material transparent and (ii) biological materials which were, after the clearing treatment, brought back to state s that they had before the clearing treatment.
- a “clearing reagent for making a biological material transparent” according to the pre sent invention is a solution containing "urea” as an essential active component for making a biological material transparent.
- a “clearing reagent for making a biological material transparent” is a solution containing a "urea derivative" as an essential active component for making a biological material transparent.
- the urea derivative is not limited to any specific kind .
- the urea derivative is any of various kinds of ureine or compounds expre ssed by Formula ( 1 ) below.
- the compounds expressed by Formula ( 1 ) include part of ureines .
- the clearing agent for making a biological material transparent according to the present invention only needs to contain , as an active component, at least one compound selected from the group consisting of urea and urea derivatives .
- the clearing agent more preferably contains urea.
- each of R l , R2 , R3 , and R4 is independently a hydrogen atom (note that the one in which all of R l through R4 are hydrogen atoms is excluded , since it corresponds to urea) , a halogen atom, or a hydrocarbon group .
- the hydrocarbon group has a plurality of carbon atoms, part of the carbon atoms may be replaced by a hetero atom such as a nitrogen atom, an oxygen atom, or a sulfur atom .
- the hydrocarbon group encompass a chain hydrocarbon group and a cyclic hydrocarbon group .
- Examples of the chain hydrocarbon group encompass a chain alkyl group, a chain alkenyl group, and a chain alkynyl group .
- the chain hydrocarbon group may have any number of carbon atoms .
- the chain hydrocarbon group may be straight-chain or branched one having 6 or less carbon atoms, preferably, an alkyl group having 1 through 3 carbon atoms .
- the chain hydrocarbon group may have a substituent such as a halogen atom.
- Examples of the chain alkyl group encompass a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an iso-butyl group , a sec-butyl group, a tert-butyl group, a hexyl group, and an octyl group .
- the cyclic hydrocarbon group may be, for example , a cycloalkyl group or a cycloalkenyl group .
- the cyclic hydrocarbon group may have a substituent such as a halogen atom.
- Examples of the cycloalkyl group encompass those having 3 or more and preferably not more than 6 carbon atoms , such as a cyclopropyl group, a cyclobutyl group, a cyclopenthyl group, and a cyclohexyl group .
- Example s of the cycloalkenyl group encompass tho se having 3 or more and preferably not more than 6 carbon atoms, such as a cyclohexenyl group .
- halogen atom encompass a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom .
- the following 1 ) and 2) are more preferable, concrete examples of the urea derivatives expressed by Formula 1 :
- Any three groups selected from R l through R4 are hydrogen atoms, and the other one group is (i) a halogen atom or (ii) a chain hydrocarbon group having 1 through 6 carbon atoms, more preferably, the other one group is an alkyl group having (i) 1 through 3 carbon atoms or (ii) 1 or 2 carbon atoms .
- Any two groups selected from R l through R4 are hydrogen atoms , and each of the other two groups is independently (i) a halogen atom or (ii) a chain hydrocarbon group having 1 through 6 carbon atoms, more preferably, both of the other two groups are alkyl groups each having (i) 1 through 3 carbon atoms or (ii) 1 or 2 carbon atoms . Further more preferably, one of the two groups which are hydrogen atoms is selected from R l and R2 , and the other of the two groups is selected from R3 and R4.
- Urea is an extremely low toxic substance derived from a living organism. Therefore , a "clearing reagent for making a biological material transparent" according to the present invention has the following advantages : 1 ) The clearing reagent of the present invention can be used to make transparent not only fixed biological materials but also non- fixed (living) biological materials . 2) Urea has a relatively low possibility of damaging fluorescent proteins and quenching of fluorescence therefrom, and therefore the clearing reagent of the present invention is also applicable to an observation of a biological material with use of a fluorescent protein . 3) Urea is quite low in cost and easily available , and furthermore is easy to handle ; therefore , use of the clearing reagent of the present invention allows a clearing treatment to be performed at an extremely low cost and by a simple procedure .
- the clearing reagent according to the present invention also has the following advantages: 4) Compared with conventional clearing reagents for making a biological material transparent, the clearing reagent of the present invention can greatly improve transparency of non-transparent biological materials having high light scattering properties, thereby enabling an observation of various fluorescent proteins and fluorescent substances existing in ultra-deep tissues . 5) Particularly, for brain tissues, use of the clearing reagent of the present invention makes it po ssible to make transparent a white matter layer, which has been a barrier against an observation of a deep portion , thereby enabling an observation of a region (e . g. , corpus callosum) located deeper than the white matter layer.
- a region e . g. , corpus callosum
- a clearing treatment using the clearing reagent of the present invention is reversible . Specifically, merely by immersing in an equilibrium salt solution a biological material having been subj ected to the clearing treatment, it is possible to bring the biological material back to a state that the biological material had before the clearing treatment. Further, before and after the clearing treatment, antigenicity of a protein and / or the like is unchanged and maintained . This allows an assay by means of a general tissue staining or immunostaining.
- a "clearing reagent for making a biological material transparent" according to the present invention may contain a surfactant, if necessary.
- the surfactant is preferably a nonionic surfactant, since the nonionic surfactant gently facilitates intrusion of the present clearing reagent into a biological tissue .
- the nonionic surfactant encompass : fatty acid surfactants such as polyoxyethylene sorbitan monolaurate , polyoxyethylene sorbitan monopalmitate , polyoxyethylene sorbitan monostearate , and polyoxyethylene sorbitan monooleate ; higher alcohol surfactants such as polyvinyl alcohol; and alkylphenol surfactants such as polyoxyethylene octylphenyl ether.
- the surfactant may be at least one selected from the group consisting of: Triton X (Registered Trademark) formula s such as Triton X- 100 and Triton X- 140 ; Tween (Registered Trademark) series such as Tween-20 , Tween-40 , Tween-60 , and Tween-80 ; and NP-40 (product name) .
- Triton X Registered Trademark
- Tween Registered Trademark
- Tween-60 trademark of Tween-60
- Tween-80 trademark name
- NP-40 product name
- the clearing reagent preferably contains a surfactant.
- a "clearing reagent for making a biological material transparent" according to the present invention may further contain a water- soluble macromolecular compound , if necessary.
- the macromolecular compound refers to the one which has a molecular weight of approximately 50 , 000 to 60 , 000 , for example , and which does not substantially intrude into cells . Further, the macromolecular compound is preferably the one which does not cause denaturation or the like of a biological material .
- the water- soluble macromolecular compound encompass a crosslinked sucro se macromolecular substance , polyethylene glycol, polyvinyl pyrrolidone , and Percoll (product name ; a macromolecular substance obtained by covering colloidal silica with a polyvinyl pyrrolidone film) .
- the crosslinked sucrose macromolecular substance encompass a macromolecular substance which is obtained by crosslinking (copolymerizing) sucrose with epichlorohydrin and which has a weight-average molecular weight of approximately 70 , 000 , such as Ficoll PM70 (product name) .
- these water- soluble macromolecular compounds do not intrude into cells . Furthermore , these water- soluble macromolecular compounds are soluble in water. Therefore , these water- soluble macromolecular compounds are considered to contribute to controlling of an osmotic pressure difference between the inside and outside of a cell. As such, each of these water- soluble macromolecular compounds helps a biological material to be subj ected to a clearing treatment maintain its original shape , and particularly contributes to prevention of swelling of the biological material.
- the clearing reagent according to the present invention preferably contains any of these water- soluble macromolecular compounds .
- the present invention is not limited to this .
- a “clearing reagent for making a biological material transparent” according to the present invention can contain a “drying inhibition component” , which is at least one compound selected from glycerol, carboxy vinyl polymer, hydroxypropyl methylcellulose, propylene glycol, and macrogol, if necessary.
- the drying inhibition component prevents drying of a biological material subj ected to a clearing treatment.
- the clearing reagent of the present invention preferably contains any of the above drying inhibition components .
- a “clearing reagent for making a biological material transparent” may contain an additive(s) such as a pH adjusting agent and / or an osmotic pressure controlling agent, if necessary. (Solvent)
- a “clearing reagent for making a biological material transparent” is a solution containing a solvent in which urea is soluble .
- the solvent is not limited to any specific kind, as long as urea is soluble in the solvent.
- water is used as a main solvent; particularly preferably, only water is used as the solvent.
- water is used as a main solvent is that a volumetric percentage of water to all solvents used is larger than that of any other solvent, and preferably that water is used in an amount which accounts for more than 50% and not more than 1 00% of a total volume of all solvents used .
- a "clearing reagent for making a biological material transparent" prepared by using water as a main solvent is referred to as a "clearing reagent for making a biological material transparent" as an aqueous solution .
- the water may be mixed with dimethyl sulfoxide (DM SO) for application to a fixed sample, for example .
- DM SO dimethyl sulfoxide
- use of a mixture of DM SO and water to a fixed sample provide s effects such as (i) improvement in permeability of the clearing reagent with respect to a biological material and (ii) facilitation of a clearing treatment with re spect to a tissue having a keratin surface .
- the use of water as the solvent significantly reduces the possibility of damaging a fluorescent protein ; this makes it possible to observe , with use of a fluorescent protein, a biological material having been subj ected to a clearing treatment.
- the use of water as the solvent makes it possible to apply the clearing reagent of the present invention not only to a clearing treatment on a fixed material but also to a clearing treatment on a living material .
- the use of water as the solvent makes a clearing treatment reversible (described later) , that is , the use of water as the solvent can bring a biological material having been subj ected to a clearing treatment back to a state that it had before the clearing treatment, if necessary. 6)
- the use of water as the solvent enhances safety in handling of the clearing reagent.
- a “clearing reagent for making a biological material transparent” according to the present invention may be a buffer which can maintain a pH suitable for a biological material to be subj ected to a clearing treatment. Further, a “clearing reagent for making a biological material transparent” according to the present invention may have an osmotic pressure adjusted to a degree which does not cause deformation of a biological material to be subj ected to a clearing treatment and which allows urea to sufficiently penetrate into the biological material.
- the above solvent can also be used for the urea derivative .
- the "clearing reagent for making a biological material transparent" according to the present invention is not particularly limited in terms of an amount of "urea” contained therein, as long as the clearing reagent with that amount of urea can proceed the clearing treatment on a biological material .
- an upper limit of the amount of urea contained in the clearing reagent is determined by the solubility of urea with respect to a solvent to be used.
- a clearing reagent with a relatively small amount of urea can perform a required treatment by performing the treatment for a long time
- a clearing reagent with a relatively large amount of urea can perform a required treatment by performing the treatment for a short time , although this depends on the type of the biological material to be subj ected to the treatment.
- a concentration of urea in a clearing reagent of the present invention is preferably 1 M or more and not more than 8.5M , more preferably 3.5M or more and not more than 8.5M , particularly preferably 4M or more and not more than 8M .
- an amount of the urea derivative (or the mixture) in the clearing agent can also be set to the same amount as that of urea.
- the clearing reagent is not particularly limited in terms of an amount of the surfactant contained therein .
- the surfactant is contained therein at a concentration of 0.025 (w/ v) % or more and not more than 5 (w/ v)% , more preferably 0.05 (w/ v)% or more and not more than 0.5(w/ v) % , particularly preferably 0.05 (w/ v)% or more and not more than 0.2 (w/ v)% .
- the unit "(w/v)%” represents a percentage of a weight (w (gram)) of a surfactant used, with respect to a volume (v (milliliter)) of the clearing reagent.
- the clearing reagent is not particularly limited in terms of an amount of water-soluble macromolecular compound contained therein.
- the water-soluble macromolecular compound is contained therein at a concentration of 2.5(w/v)% or more and not more than 40(w/v)%.
- the above concentration is more preferably 5(w/v)% or more and not more than 25(w/v)%, further more preferably 10(w/v)% or more and not more than 20(w/v)%, particularly preferably 10(w/v)% or more and not more than 15(w/v)%.
- the unit "(w/v)%” represents a percentage of a weight (w (gram)) of the water-soluble macromolecular compound used, with respect to a volume (v (milliliter)) of the clearing reagent.
- the clearing reagent is not particularly limited in terms of an amount of the drying inhibition component contained therein.
- the drying inhibition component is contained therein at a concentration of 2.5(w/v)% or more and not more than 20(w/v)%, more preferably 5(w/v)% or more and not more than 15(w/v)%, particularly preferably 8(w/v)% or more and not more than 12(w/v)%.
- the unit (w/v)% represents a percentage of a weight (w (gram)) of the drying inhibition component used, with respect to a volume (v (milliliter)) of the clearing reagent.
- a biological material to be subjected to a clearing treatment using a "clearing reagent for making a biological material transparent" of the present invention is not limited to any specific kind.
- the biological material is a material derived from a plant or an animal, more preferably a material derived from an animal such as the one selected from fish, amphibians, reptiles, birds, and mammals, particularly preferably a material derived from a mammal.
- the mammal is not limited to any specific kind, examples of which encompass: laboratory animals such as mice, rats, rabbits, guinea pigs, and primates except for humans; pet animals such as dogs and cats; farm animals such as cows and horses; and humans.
- the biological material may be an individual itself (except for a living human individual). Further alternatively, the biological material may be an organ, a tissue, or a cell taken from an individual of a multicellular organism.
- a "clearing reagent for making a biological material transparent" of the present invention has excellent ability to make a subject transparent; therefore, even if the biological material is a tissue or an organ (e.g., the whole of or part of a brain) derived from a multicellular animal or an individual itself (e.g., an embryo) of a multicellular animal which is not a human, the biological material can be subjected to a clearing treatment.
- the biological material may be either of (i) a material fixed for a telescopic observation and (ii) a non- fixed material.
- the material is preferably immersed in, e.g., a 20(w/v)% sucrose- PBS solution adequately (e.g., for 24 hours or more) after being subjected to a fixing process.
- this material is embedded into an OCT compound and frozen by liquid nitrogen, thawed in PBS, and then fixed again by a 4(w/v)% PFA-PBS solution.
- the biological material encompass: a biological tissue having a fluorescent chemical substance injected thereto; a biological tissue stained with a fluorescent chemical substance; a biological tissue having a fluorescent protein-expressed cell transplanted thereto; and a biological tissue taken from a genetically-modified animal in which a fluore scent protein is expressed .
- clearing reagents are quite suitable for a clearing treatment particularly on the whole of or part (e . g. , the hippocampus or the whole or part of the cerebrum) of the brain or an embryo of a mammal such as a mouse .
- clearing reagents for making a biological material transparent used in Examples 1 to 9 also satisfied the following conditions of the below-described clearing reagents ( 1 ) to (4) :
- urea at a concentration of 4 M or more and not more than 8M
- a nonionic surfactant e . g. , Triton X- 100
- a drying inhibition component e.g., glycerol
- a nonionic surfactant e.g., Triton X-100
- a drying inhibition component e.g., glycerol
- a water-soluble macromolecular compound e.g., Ficoll
- urea at a concentration of 4M or more and not more than 8M
- a nonionic surfactant e.g., Triton X-100
- DMSO dimethyl sulfoxide
- the clearing reagents ( 1 ) through (4) may be prepared with the urea derivative (or the mixture) at the same concentration as the above-described concentration of urea.
- a method for preparing a "clearing reagent for making a biological material transparent” includes dissolving, in a solvent, (i) "urea and / or a urea derivative” and (ii) a “surfactant” , a "water-soluble macromolecular compound” , a “drying inhibition component” , and / or the like, each of which is used if necessary.
- a procedure for dissolving or mixing the component(s) in the solvent is not particularly limited .
- a method for a clearing treatment on a biological material with use of a "clearing reagent for making a biological material transparent" includes a step (clearing treatment step) for causing the clearing reagent to permeate into the biological material. More specifically, this step causes the clearing reagent to permeate into the biological material in a container for a clearing treatment.
- whether the clearing reagent or the biological material is stored in the container for the clearing treatment first is not particularly limited .
- the clearing reagent is stored in the container first, and subsequently the biological material is stored therein (i. e . , the biological material is put into the clearing reagent) .
- a processing temperature at which the above clearing treatment step is performed is not particularly limited ; preferably, the processing temperature is within a range of 15°C or more and not more than 45°C .
- a processing time for which the clearing treatment is performed is not particularly limited ; preferably, the processing time is within a range of two hours or more and not more than six months , more preferably 12 hours or more and not more than seven days .
- a pressure at which the clearing treatment is performed is not particularly limited.
- the container for the clearing treatment which is used in the above clearing treatment step and in which the biological material having been subj ected to the clearing treatment is stored may be preserved , e . g. , at room temperature or in a low-temperature environment until the container is used in the below-described observation step .
- a step for preserving a sample after a clearing treatment A step for preserving a sample after a clearing treatment
- an observation step by, e . g. , an optical micro scope is subsequently performed .
- a visualizing treatment step e . g. , staining or marking
- a fluorescent protein gene is transferred into a living biological material before the clearing treatment step so that the fluorescent protein will be expressed therein.
- the visualizing treatment step is (i) inj ection of a fluorescent chemical substance (which is not a fluorescent protein) into a biological material or (ii) staining of a biological material with a fluorescent chemical substance
- the visualizing treatment step is preferably performed before the clearing treatment step .
- the visualizing treatment step may be performed after the clearing treatment step .
- the visualizing treatment step may be staining of a biological material with a chemical substance which is not a fluorescent chemical substance .
- the observation step can be performed with use of any type of optical microscope .
- the observation step can be performed by employing a three-dimensional super- resolution microscopy technique (e.g., STED, 3D PALM, FPALM, 3D STORM, or SIM).
- the observation step is performed by employing a multi-photon excitation type (generally, two-photon excitation type) optical microscopy technique.
- a clearing treatment using a "clearing reagent for making a biological material transparent" according to the present invention is reversible.
- a biological material having been subjected to the clearing treatment can be brought back to a state that it had before the clearing treatment, e.g., by immersing the biological material in an equilibrium salt solution so as to remove therefrom the components of the clearing reagent.
- equilibrium salt solution encompass: equilibrium salt solutions (e.g., PBS and HBSS) which are buffered by phosphate; an equilibrium salt solution (TBS) which is buffered by tris hydrochloride; an artificial cerebrospinal fluid (ACSF); and basal media for cell culturing, such as MEM, DMEM, and Ham's F-12.
- equilibrium salt solutions e.g., PBS and HBSS
- TBS equilibrium salt solution
- ASF artificial cerebrospinal fluid
- basal media for cell culturing such as MEM, DMEM, and Ham's F-12.
- the use of the clearing reagent does not cause denaturation or the like of a protein, etc. in the biological material, before and after the clearing treatment, or in a case where, after the clearing treatment, the biological material is brought back to a state that it had before the clearing treatment. Accordingly, antigenicity of the protein, etc . in the biological material is preserved as unchanged .
- the biological material can be brought back to a state that it had before the clearing treatment, so as to undergo , e . g. , a detailed assay by means of generally-used tissue staining or immuno staining.
- a “kit for a clearing treatment for making a biological material transparent” includes the above-described “clearing reagent for making a biological material transparent” .
- the “kit for a clearing treatment for making a biological material transparent” may further include at least one selected from : a “container for a clearing treatment” used in the clearing treatment step; a “biological material holding tool (e . g. , tweezers)” ; an "equilibrium salt solution” for bringing a biological material having been subj ected to a clearing treatment back to a state that it had before the clearing treatment; and an "instruction manual for the kit” .
- a system for a clearing treatment for making a biological material transparent according to the present invention includes : a "clearing reagent for making a biological material transparent" according to the present invention; and the above-described "biological material" which has been isolated . Further, in this system, the clearing reagent has permeated into the biological material so as to make the biological material transparent. That is , a concept of this system for a clearing treatment encompasses, e . g. , (i) a treatment system including a biological material which is in a midterm stage of a clearing treatment or (ii) a treatment system including a biological material on which a clearing treatment has been completed .
- a clearing reagent for making a biological material transparent includes, as an active component, at least one compound selected from the group consisting of urea and urea derivatives , the clearing reagent being a solution .
- urea is more preferably contained as the active component.
- the clearing reagent for making a biological material transparent according to the present invention is more preferably an aqueous solution.
- the clearing reagent for making a biological material transparent according to the pre sent invention having the above arrangement, more preferably include s a surfactant.
- the surfactant is more preferably a nonionic surfactant.
- the nonionic surfactant is more preferably at least one selected from the group consisting of Triton X (Registered Trademark) , Tween (Registered Trademark) , and NP-40 (product name) .
- the clearing reagent for making a biological material transparent according to the present invention more preferably includes a water- soluble macromolecular compound .
- the water- soluble macromolecular compound is more preferably at least one selected from the group consisting of Percoll (Registered Trademark) , Ficoll (Registered Trademark) , polyethylene glycol, and polyvinyl pyrrolidone .
- the urea is more preferably contained at a concentration of 1 M or more and not more than 8.5M
- the surfactant is more preferably contained at a concentration of 0.025 (w/ v)% or more and not more than 5 (w/ v) %
- the water-soluble macromolecular compound is more preferably contained at a concentration of 2.5 (w/ v)% or more and not more than 40 (w/ v)% .
- the clearing reagent for making a biological material transparent more preferably further includes at least one selected from the group consisting of glycerol, carboxy vinyl polymer, hydroxypropyl methylcellulose, propylene glycol, and macrogol.
- the clearing reagent for making a biological material transparent preferably makes transparent (i) a tissue or an organ derived from a multicellular animal or (ii) a multicellular animal which is not a human.
- the present invention also provides a system for a clearing treatment for making a biological material transparent, including: any of the above clearing reagents ; and a biological material which has been isolated , the clearing reagent having permeated into the biological material in order to make the biological material transparent.
- a method according to the pre sent invention for making a biological material transparent includes the step of: causing any of the above clearing reagents to permeate into a biological material which has been isolated, in order that the biological material is made transparent.
- a method according to the present invention for recovering a biological material having been made transparent by a clearing treatment include s the step of: causing an equilibrium salt solution to permeate into a biological material having been made transparent according to the above method, in order that the biological material is brought back to a state that the biological material had before the clearing treatment.
- the present invention also provides a kit for a clearing treatment for making a biological material transparent, including any of the above clearing reagents .
- a transgenic mouse having a fluorescent protein YFP expressed in its neurons of the nervous system (YFP- H line : provided by Professor Jo sh Sanes of Harvard University, U . S .A. [reference] Feng et al. Neuron , 28 : 4 1 - 5 1 , 2000) of 7 to 8 week-old after birth was used .
- a peristaltic pump was used to perfuse an ice-cold PBS from the left cardiac ventricle of the mouse , and then to perfuse an ice-cold fixing solution (4% paraformaldehyde-PBS, pH 7.4) , so that the mouse was systemically fixed .
- the cranial bones were removed from the mouse , and the hippocampus was carefully taken out therefrom. Then, the hippocampus taken out was immersed in an ice-cold fixing solution (4% paraformaldehyde- PBS , pH 7.4) for one night at 4°C . Thereafter, the hippocampus was transferred into a 20% sucrose-PBS solution, and was then gently shaken for 24 hours at 4°C .
- an ice-cold fixing solution 4% paraformaldehyde- PBS , pH 7.4
- the hippocampus was embedded into an OCT compound, and was then frozen by liquid nitrogen . Then , the frozen hippocampus was put into PBS , and was thawed at room temperature . The hippocampus thawed was refixed in a 4% paraformaldehyde- PBS for an hour.
- the clearing reagent was an aqueous solution prepared by dissolving 4M urea in pure water.
- the hippocampus was embedded in agaro se gel (concentration: 0.5% (w/ v) or less) , and was observed from its bottom side to top surface side with use of an upright two-photon microscope (product name : FV 1000MPE, manufactured by Olympus Corporation) provided with a laser having a wavelength of 920 nm. Note that an obj ective lens used in the observation had a working distance of 2 mm .
- Fig. 1 The result of the observation is shown in Fig. 1 .
- performing the clearing treatment with use of the clearing reagent according to the present example could allow a clear observation of a range of approximately 1 .9 mm in depth (corresponding to the thickness of the biological material) , the range covering the dentate gyrus (DG) , the CA l , and the top surface of the hippocampus .
- DG dentate gyrus
- Example 2 used, as the clearing reagent used in the "Step for Clearing Treatment for Making Biological Material Transparent" , an aqueous solution (referred to as a SCALE-A2 reagent) prepared by dissolving, in pure water, 4M urea, 0. 1 %(w/ v) Triton X- 100 , and 10%(w/ v) glycerol and (ii) Example 2 performed an observation from the top surface side to the bottom side of the hippocampus.
- SCALE-A2 reagent an aqueous solution prepared by dissolving, in pure water, 4M urea, 0. 1 %(w/ v) Triton X- 100 , and 10%(w/ v) glycerol
- the clearing treatment with use of the clearing reagent according to the pre sent example could allow a clear observation of a range of approximately 2 mm in depth (corresponding to the thickness of the biological material) , the range covering the top surface , the CA 1 , the dentate gyrus (DG) , and the bottom of the hippocampus .
- a mouse cerebrum was observed according to the same method as that of Example 1 , except for the following points 1 ) to 3) :
- Example 3 In the "Step for Taking-Out and Fixing of Biological Material" of Example 3 , the whole of the cerebrum was taken out and fixed , and the cerebrum fixed was used as a biological material.
- Example 3 In the "Step for Clearing Treatment and Observation of Biological Material" of Example 3 , a SCALE-A2 reagent identical to the one used in Example 2 was used as a clearing reagent for making a biological material transparent 3) In the "Step for Clearing Treatment and Observation of Biological Material” of Example 3 , an obj ective lens having a working distance of 3 mm was used to perform an observation from the cerebrum top surface (cerebral cortex) side to the hippocampus side .
- Fig. 3 The result of the observation is shown in Fig. 3.
- performing the clearing treatment with use of the clearing reagent according to the present example could allow a clear observation of a range of approximately 3 mm in depth (a working limit of the objective lens) , the range covering, of course, the cerebral cortex and the layer V-VI , and further covering the white matter region (corpus callosum) below the cerebral cortex, the fiber tract of the hippocampus, and even a cell group constituting the CA 1 of, the dentate gyrus (DG) , etc .
- DG dentate gyrus
- a mouse cerebrum was subj ected to a clearing treatment with use of a SCALE-A2 reagent, according to the same method as that described in Example 3 except that the clearing treatment was carried out for two days . Then, a volume of the cerebrum having been subj ected to the clearing treatment was measured . Note that, the two-day clearing treatment was sufficient to make the mouse cerebrum transparent to a degree allowing an observation .
- a mouse cerebrum was immersed in PB S , and a volume thereof was measured immediately after the immersion (0 day after the immersion) .
- Fig. 4 shows that, in comparison with the control (indicated as "PB S” in Fig. 4) , the cerebrum (indicated as "SCALE-A2" in Fig. 4) having been subj ected to the above treatment 1 ) swelled . Meanwhile , swelling of the cerebrum having been subjected to the above treatment 2) was reduced according to the amounts of Ficoll added.
- the use of the clearing reagent having 20% (w/ v) Ficoll added thereto reduced the swelling by 85% or more (indicated as "SCALE- A2 + 20% Ficoll” in Fig. 4) .
- the cerebrum which has not swelled or retracted is particularly preferable; however, the cerebrum which has swelled or retracted can also be observable as a sample by an optical micro scope .
- a mouse cerebrum was observed according to the same method as that of Example 1 except for the following points 1 ) and 2) :
- a clearing reagent for making a biological material transparent was an aqueous solution prepared by dissolving, in pure water, 4M urea, 0. 1 %(w/ v) Triton X- 100 , 1 0%(w/ v) glycerol, and 10%(w/ v) Ficoll, and a clearing treatment was performed for three days .
- Example 5 In the "Step for Clearing Treatment and Observation of Biological Material" of Example 5 , an obj ective lens having a working distance of 2 mm was used to perform an observation from the cerebrum top surface (cerebral cortex) side to the hippocampus side .
- the clearing treatment with use of the clearing reagent according to the present example could allow a clear observation of a range of approximately 2.16 mm in depth (a working limit of the objective lens), the range covering, of course, the cerebral cortex and the layer V-VI, and further covering the white matter region (corpus callosum) below the cerebral cortex, the fiber tract of the hippocampus, and even a cell group constituting the CA1, etc.
- Mouse brain slices were treated for one day with (i) water, (ii) PBS, (iii) an 8M urea aqueous solution (clearing reagent), (iv) a 4M urea aqueous solution (clearing reagent), (v) a clearing reagent SCALE-A2 (an aqueous solution containing 4M urea, 0.1%(w/v) Triton X-100, and 10%(w/v) glycerol), and (vi) a clearing reagent SCALE-D2 (an aqueous solution containing 4M urea + 0.1%(w/v) Triton X-100 and 10%(w/v) DMSO), respectively.
- SCALE-A2 an aqueous solution containing 4M urea, 0.1%(w/v) Triton X-100, and 10%(w/v) glycerol
- SCALE-D2 an aqueous solution containing 4M urea + 0.1%
- a transmittance of a cerebral cortex portion of each mouse brain slice with respect to light having a wavelength of 200 nm to 1000 nm was measured.
- a light wavelength band from 200 nm to 1000 nm covers both of (i) an excitation wavelength range commonly used in a two- photon microscopic observation and (ii) a range of a main fluorescence wavelength of a fluorescent protein to be observed.
- a Fucci-S-Green (Fucci-S/G2/M)-expressed transgenic mouse fetus at 13.5 days of fetal life obtained by breeding of mice produced by Laboratory for Cell Function Dynamics, Brain Science Institute, RIKEN [reference: Sakaue-Sawano et al., Cell, 132(3): 487-98, 2008.] was fixed with 4(w/v)% PFA-PBS for two days, and was then immersed in a 20(w/v)% sucrose-PBS solution. Thereafter, the fetus was frozen once, and was then thawed. After that, the fetus was fixed again with 4(w/v)% PFA-PBS for an hour. Subsequently, the fetus was immersed in SCALE-A2 described in Example 2 for seven days for a clearing treatment.
- the fetus was embedded in agarose gel (concentration: 0.5%(w/v) or less), and was observed with use of a fluorescent stereomicroscope (product name: MZ10F, manufactured by Leica Microsystems). Note that an objective lens used in the observation had a working distance of 70 mm.
- Fig. 7 As shown in Fig. 7, by performing the clearing treatment with use of the clearing reagent according to the present example, the whole body of the mouse fetus was made transparent outstandingly, although only the liver thereof had a small yellow portion left. Note that the mounting rubber (mr) shown in Fig. 7 was used to support the head of the mouse fetus.
- a Fucci-S-Green (Fucci-S/G2/ M)-expressed transgenic mouse of six week-old after birth was used.
- a peristaltic pump was used to perfuse an ice-cold PBS from the left cardiac ventricle of the mouse, and then to perfuse an ice- cold fixing solution (4% paraformaldehyde- PBS , pH 7.4) , so that the mouse was fixed systemically .
- the cranial bone was removed from the mouse , and the dentate gyrus of hippocampus was carefully taken out therefrom. Then , the dentate gyrus of hippocampus taken out was immersed in an ice-cold fixing solution (4% paraformaldehyde- PBS , pH 7.4) for one night at 4°C . Thereafter, the dentate gyrus of hippocampus was transferred into a 20% sucrose-PBS solution, and was then gently shaken for 24 hours at 4°C .
- an ice-cold fixing solution 4% paraformaldehyde- PBS , pH 7.4
- the dentate gyrus of hippocampus was embedded into an OCT compound, and was then frozen by liquid nitrogen . Then , the dentate gyrus of hippocampus frozen was put into PBS , and was thawed at room temperature . The dentate gyrus of hippocampus unfrozen was refixed in a 4% paraformaldehyde-PBS for an hour.
- the blood vessels of the dentate gyrus used in the present example were stained with Lectin-Texas Red conjugate .
- the dentate gyrus of hippocampus refixed was immersed for three days in a clearing reagent according to the present example for making a biological material transparent, and was shaken at room temperature.
- the clearing reagent was an aqueous solution prepared by dissolving, in pure water, 4M urea, 0.1%(w/v) Triton X-100, and 10%(w/v) glycerol.
- the dentate gyrus of hippocampus was embedded in agarose gel (concentration: 0.5%(w/v) or less), and was observed with use of an upright two-photon microscope (product name: FV1000MPE, manufactured by Olympus Corporation) provided with a laser having a wavelength of 920 nm. Note that an objective lens used in the observation had a working distance of 2 mm. The observation was performed on 18 consecutive visual fields, from the ventral side of the hippocampus to 1.7 mm-depth. Then, the results of the observation were combined into an integrated image.
- Fig. 8 The result of the observation is shown in Fig. 8. As shown in Fig. 8, it was confirmed that the clearing treatment with use of the clearing reagent according to the present example allowed to observe that Fucci-S-Green (Fucci- S/ G2/ M)-positive neural progenitor cells existed around the blood vessels.
- Example 9 Observation Regarding Transplantation of Neural Progenitor Cells
- Neural progenitor cells derived from the hippocampus of a fluorescent protein Venus-expressed adult rat were obtained .
- the neural progenitor cells obtained were transplanted into a cerebral cortex portion (in the vicinity of the layer V, approximately 1 .7 mm in depth) of a Fischer F344- strain rat (purchased from Japan SLC , Inc . ) .
- the Fischer F344- strain rat was fixed according to the method described in the (Step for Perfusion Fixation) of Example 8. Subsequently, according to the method described in the (Step for Taking-Out and Fixing of Biological Material) of Example 8 , the cerebral cortex of the Fischer F344- strain rat was fixed. Note that the blood vessels of the rat cerebral cortex used in the present example were stained with Lectin-Texas Red conjugate .
- Example 8 the cerebral cortex was observed .
- the result of the observation is shown in Fig. 1 1 .
- performing the clearing treatment with use of the clearing reagent according to the present example allowed to observe that fluorescence protein Venus-expressed neural progenitor cells had gathered in the vicinity of the blood vessels (stained with Lectin Texas-Red conjugate) .
- the pre sent method is suitable for an observation of movement of cells after transplantation, changes in the morphology, and the like.
- mice each having a fluorescent protein YFP expressed in its nervous system (YFP-H line: provided by Professor Josh Sanes of Harvard University, U.S.A. [reference] Feng et al. Neuron, 28: 41-51, 2000) of 12 week- old after birth were used. From the mice, the cerebra were taken out. Then, a clearing treatment using a SCALE-A2 reagent (the present invention: see Example 2) was compared with a clearing treatment according to a benzylbenzoate/benzylalchol (BABB) method described by Dodt et al. in Non-Patent Literature 2.
- BABB benzylbenzoate/benzylalchol
- the clearing treatment using the SCALE-A2 reagent maintained 80% or more of the fluorescence intensity from the fluorescent protein.
- the clearing treatment according to the BABB method caused a significant reduction in the fluorescence intensity from the fluorescent protein.
- the immunostaining was performed as follows : As a primary antibody, (i) mouse-derived anti-polysialilated neural cell adhesion molecule (PSA-NCAM) monoclonal antibody (Millipore Corporation) that recognizes a polysialic acid of PSA-NCAM existing on a surface of an immature neuronal cell and (ii) rabbit-derived anti-glial fibrillary acidic protein (GFAP) polyclonal antibody (Sigma-Aldrich) that recognizes an intermediate filament GFAP specific to astroglia were used, and were caused to react with their respective target proteins in the slices for 24 hours at 4°C . Thereafter, the slices were rinsed with PBS .
- PSA-NCAM mouse-derived anti-polysialilated neural cell adhesion molecule
- GFAP rabbit-derived anti-glial fibrillary acidic protein
- the anti- PSA- NCAM monoclonal antibody was caused to react with an Alexa Fluor 546-labeled anti-mouse IgM antibody (Invitrogen, Molecular Probes) , which was used as a secondary antibody, at room temperature for three hours; and the GFAP polyclonal antibody was caused to react with an Alexa Fluor 633 -labeled anti-rabbit IgG antibody (Invitrogen, Molecular Probe s) , which was used as a secondary antibody, at room temperature for three hours .
- the slices were immunohistochemically stained. Since fluorescence from these slices did not decayed, triple fluorescent (fluorescence including GFP and YFP) stained images were obtained .
- the observation was performed with a 20-power obj ective lens (UplanApo20 , Olympus Corporation) with use of an inverted confocal laser micro scope (FV500, Olympus Corporation) .
- the present invention provides : a novel clearing reagent for making a biological material transparent which clearing reagent contains , as an active component, a component having a higher bio-affinity; and use thereof.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
A clearing reagent according to this invention for making a biological material transparent is a solution containing, as an active component, at least one compound selected from the group consisting of urea and urea derivatives, in order to provide a novel clearing reagent for making a biological material transparent.
Description
Description
Title of Invention
CLEARING REAGENT FOR BIOLOGICAL MATERIAL, AND USE TH EREOF
Technical Field
The present invention relates to a clearing reagent for making a biological material transparent, and use thereof.
Background Art
For an internal observation of a non-transparent tissue with use of an optical microscope , a pretreatment (a clearing treatment for making a subj ect transparent) using a clearing reagent is performed .
As typical examples of the clearing reagent and the pretreatment method, there have been known (i) a Focus Clear (product name) solution described by Ann- Shyn Chiang in Patent Literature 1 and Non-Patent Literature 1 and (ii) a tissue clearing method described by Hans-Ulrich Dodt et al . in Non- Patent Literature 2. These are both used to make a tissue transparent for an observation of a fluorescent substance existing in the tissue .
Citation List
[Patent Literature]
U.S. Patent No. 6472216 (Date of patent: October 29, 2002)
[Non-Patent Literature]
Non-Patent Literature 1
Ann-Shyn Chiang et al.: Insect NMDA receptors mediate juvenile hormone biosynthesis. PNAS 99(1), 37-42 (2002).
Non-Patent Literature 2
Hans-Ulrich Dodt et al.: Ultramicroscopy : three- dimensional visualization of neuronal networks in the whole mouse brain. Nature Methods 4 (4), 331-336 (2007).
Summary of Invention
Technical Problem
The Focus Clear solution, which contains dimethyl sulfoxide (DMSO) and/or the like as an active component for making a subject transparent, is difficult to be used on living tissues. Therefore, subjects to which the Focus Clear solution can be applied are limited largely to fixed samples.
In addition, the Focus Clear solution has a quite complicated composition, whereby preparation thereof is complicated, and its cost is very high. Furthermore, although it is suggested that the Focus Clear solution would allow an observation using a fluorescent protein, the Focus Clear solution shrinks nervous tissues and does not sufficiently clear turbidity of nervous tissue at deep area.
Meanwhile , the tissue clearing method of Dodt et al. essentially requires use of a large amount of an organic solvent in a step for making a subj ect transparent. Therefore , this method is also difficult to be used on living tissues, and subj ects to which this method can be applied are limited largely to fixed samples.
Further, as described above , since the tissue clearing method essentially requires use of a large amount of an organic solvent, this method damages almost all fluorescent proteins . As such, with this method , it is difficult to perform a tissue observation using a fluorescent protein.
Moreover, the tissue clearing method described above involve s dehydration of a tissue subj ected to a clearing treatment, which is due to the nature of their compositions . However, this process causes irreversible shrinkage of the tissue .
The present invention was made in order to solve the foregoing problems , and an obj ect of the present invention is to provide : a novel clearing agent for making a biological material transparent which clearing agent contains, as an active component, a component having a higher bio-affinity; and use thereof.
Solution to Problem
In order to solve the foregoing problems, the inventors of the present invention made diligent studies to reach a new
finding that, among components having excellent bio- affinities , urea has ability to make a biological material transparent. Based on this, the present inventors arrived at the present invention .
Specifically, a clearing reagent for making a biological material transparent according to the present invention includes, as an active component, at least one compound selected from the group consisting of urea and urea derivatives, the clearing reagent being a solution .
The present invention also provides a system for a clearing treatment for making a biological material transparent, including: any of the above clearing reagents ; and a biological material which has been isolated, the clearing reagent having permeated into the biological material in order to make the biological material transparent.
A method according to the present invention for making a biological material transparent includes the step of: causing any of the above clearing reagents to permeate into a biological material which has been isolated, in order that the biological material is made transparent.
A method according to the present invention for recovering a biological material having been made transparent by a clearing treatment includes the step of: causing an equilibrium salt solution to permeate into a biological material having been made transparent according
to the above method , in order that the biological material is brought back to a state that the biological material had before the clearing treatment.
The present invention also provides a kit for a clearing treatment for making a biological material transparent, including any of the above clearing reagents .
Advantageous Effects of Invention
The present invention provides : a novel clearing reagent for making a biological material transparent which clearing reagent contains , as an active component, a component having a higher bio-affinity; and use thereof.
Brief Description of Drawings
Fig. 1
Fig. 1 , related to an example of the present invention, is a view showing a mouse hippocampus treated with a clearing reagent according to the present invention for making a biological material transparent.
Fig. 2
Fig. 2 , related to another example of the present invention, is a view showing a mouse hippocampus treated with a clearing reagent according to the present invention for making a biological material transparent.
Fig- 3
Fig. 3 , related to further another example of the
pre sent invention, is a view showing the whole of a mouse cerebrum treated with a clearing reagent according to the present invention for making a biological material transparent.
Fig. 4
Fig. 4 , related to still further another example of the present invention, is a graph illustrating a relationship between (i) a clearing reagent according to the present invention for making a biological material transparent and (ii) swelling of a biological material treated with the clearing reagent.
Fig. 5
Fig. 5 , related to yet another example of the present invention, is a view showing the whole of a mouse cerebrum treated with a clearing reagent according to the present invention for making a biological material transparent.
Fig. 6
Fig. 6 , related to still yet another example of the present invention, is a graph showing the result of light transmittance measurement of mouse brain slices having been treated with clearing reagents according to the present invention for making a biological material transparent.
Fig. 7
Fig. 7 , related to an additional example of the present invention, is a view showing a mouse fetal treated with a
clearing reagent according to the pre sent invention for making a biological material transparent.
Fig. 8
Fig. 8 , related to a further additional example of the present invention, is a view showing the result of an observation of the neural progenitor cells in a mouse hippocampus treated with a clearing reagent according to the present invention for making a biological material transparent.
Fig. 9
Fig. 9 is a view for comparison between mouse cerebrum sample s treated with a clearing reagent according to the present invention for making a biological material transparent, or with a conventional technique (BABB method) .
Fig. 1 0
Fig. 10 is a view for comparison between the results of HeLa cells having various fluorescent proteins expre ssed therein , the HeLa cells having been treated with a clearing reagent according to the present invention for making a biological material transparent or with a conventional technique (BABB method) .
Fig. 1 1
Fig. 1 1 , related to a still further additional example of the present invention , is a view showing the result of an
observation of a cerebral cortex having neural progenitor cells transplanted thereto , which cerebral cortex was treated with a clearing reagent according to the present invention for making a biological material transparent.
Fig. 12
Fig. 12 , related to a yet additional example of the present invention, is a view showing the results of immunostaining on (i) biological materials before a clearing treatment with a clearing reagent according to the present invention for making a biological material transparent and (ii) biological materials which were, after the clearing treatment, brought back to state s that they had before the clearing treatment.
Description of Embodiments
The following will describe an embodiment of the present invention in detail.
(Active Component of Clearing Reagent for Making Biological Material Transparent)
A "clearing reagent for making a biological material transparent" according to the pre sent invention is a solution containing "urea" as an essential active component for making a biological material transparent.
A "clearing reagent for making a biological material transparent" according to another aspect of the present
invention is a solution containing a "urea derivative" as an essential active component for making a biological material transparent.
The urea derivative is not limited to any specific kind . Concretely, for example , the urea derivative is any of various kinds of ureine or compounds expre ssed by Formula ( 1 ) below. Note that the compounds expressed by Formula ( 1 ) include part of ureines . The clearing agent for making a biological material transparent according to the present invention only needs to contain , as an active component, at least one compound selected from the group consisting of urea and urea derivatives . Among these, the clearing agent more preferably contains urea.
In a urea derivative expressed by Formula ( 1 ) , each of R l , R2 , R3 , and R4 is independently a hydrogen atom (note that the one in which all of R l through R4 are hydrogen atoms is excluded , since it corresponds to urea) , a halogen atom, or a hydrocarbon group . Further, in a case where the hydrocarbon group has a plurality of carbon atoms, part of the carbon atoms may be replaced by a hetero atom such as a nitrogen atom, an oxygen atom, or a sulfur atom . Examples of the hydrocarbon group encompass a chain hydrocarbon
group and a cyclic hydrocarbon group .
Examples of the chain hydrocarbon group encompass a chain alkyl group, a chain alkenyl group, and a chain alkynyl group . The chain hydrocarbon group may have any number of carbon atoms . For example, the chain hydrocarbon group may be straight-chain or branched one having 6 or less carbon atoms, preferably, an alkyl group having 1 through 3 carbon atoms . The chain hydrocarbon group may have a substituent such as a halogen atom. Examples of the chain alkyl group encompass a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an iso-butyl group , a sec-butyl group, a tert-butyl group, a hexyl group, and an octyl group .
The cyclic hydrocarbon group may be, for example , a cycloalkyl group or a cycloalkenyl group . The cyclic hydrocarbon group may have a substituent such as a halogen atom. Examples of the cycloalkyl group encompass those having 3 or more and preferably not more than 6 carbon atoms , such as a cyclopropyl group, a cyclobutyl group, a cyclopenthyl group, and a cyclohexyl group . Example s of the cycloalkenyl group encompass tho se having 3 or more and preferably not more than 6 carbon atoms, such as a cyclohexenyl group .
Examples of the halogen atom encompass a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom .
The following 1 ) and 2) are more preferable, concrete examples of the urea derivatives expressed by Formula 1 :
1 ) Any three groups selected from R l through R4 are hydrogen atoms, and the other one group is (i) a halogen atom or (ii) a chain hydrocarbon group having 1 through 6 carbon atoms, more preferably, the other one group is an alkyl group having (i) 1 through 3 carbon atoms or (ii) 1 or 2 carbon atoms .
2) Any two groups selected from R l through R4 are hydrogen atoms , and each of the other two groups is independently (i) a halogen atom or (ii) a chain hydrocarbon group having 1 through 6 carbon atoms, more preferably, both of the other two groups are alkyl groups each having (i) 1 through 3 carbon atoms or (ii) 1 or 2 carbon atoms . Further more preferably, one of the two groups which are hydrogen atoms is selected from R l and R2 , and the other of the two groups is selected from R3 and R4.
(Advantages of Use of Urea and / or the Like as Active Component)
Urea is an extremely low toxic substance derived from a living organism. Therefore , a "clearing reagent for making a biological material transparent" according to the present invention has the following advantages : 1 ) The clearing reagent of the present invention can be used to make transparent not only fixed biological materials but also non-
fixed (living) biological materials . 2) Urea has a relatively low possibility of damaging fluorescent proteins and quenching of fluorescence therefrom, and therefore the clearing reagent of the present invention is also applicable to an observation of a biological material with use of a fluorescent protein . 3) Urea is quite low in cost and easily available , and furthermore is easy to handle ; therefore , use of the clearing reagent of the present invention allows a clearing treatment to be performed at an extremely low cost and by a simple procedure .
In addition to these advantages , the clearing reagent according to the present invention also has the following advantages: 4) Compared with conventional clearing reagents for making a biological material transparent, the clearing reagent of the present invention can greatly improve transparency of non-transparent biological materials having high light scattering properties, thereby enabling an observation of various fluorescent proteins and fluorescent substances existing in ultra-deep tissues . 5) Particularly, for brain tissues, use of the clearing reagent of the present invention makes it po ssible to make transparent a white matter layer, which has been a barrier against an observation of a deep portion , thereby enabling an observation of a region (e . g. , corpus callosum) located deeper than the white matter layer. 6) A clearing treatment using
the clearing reagent of the present invention is reversible . Specifically, merely by immersing in an equilibrium salt solution a biological material having been subj ected to the clearing treatment, it is possible to bring the biological material back to a state that the biological material had before the clearing treatment. Further, before and after the clearing treatment, antigenicity of a protein and / or the like is unchanged and maintained . This allows an assay by means of a general tissue staining or immunostaining.
Note that using, instead of urea, the above-described urea derivative can provide the similar effects .
(Surfactant)
A "clearing reagent for making a biological material transparent" according to the present invention may contain a surfactant, if necessary. The surfactant is preferably a nonionic surfactant, since the nonionic surfactant gently facilitates intrusion of the present clearing reagent into a biological tissue . Examples of the nonionic surfactant encompass : fatty acid surfactants such as polyoxyethylene sorbitan monolaurate , polyoxyethylene sorbitan monopalmitate , polyoxyethylene sorbitan monostearate , and polyoxyethylene sorbitan monooleate ; higher alcohol surfactants such as polyvinyl alcohol; and alkylphenol surfactants such as polyoxyethylene octylphenyl ether. Specifically, for example , the surfactant may be at least one
selected from the group consisting of: Triton X (Registered Trademark) serie s such as Triton X- 100 and Triton X- 140 ; Tween (Registered Trademark) series such as Tween-20 , Tween-40 , Tween-60 , and Tween-80 ; and NP-40 (product name) . As the surfactant, a mixture of two or more kinds may be used, if necessary.
These surfactants can enhance permeability of urea with respect to a biological material, thereby improving efficiency of the clearing treatment. In particular, in a clearing treatment on a biological material (e . g. , a white matter layer of brain tissues) on which a clearing treatment is relatively difficult, the clearing reagent preferably contains a surfactant.
Note that, as with the case of urea, above surfactants can enhance permeability of the urea derivative with respect to a biological material.
(Water- Soluble Macromolecular Compound)
A "clearing reagent for making a biological material transparent" according to the present invention may further contain a water- soluble macromolecular compound , if necessary. Here, the macromolecular compound refers to the one which has a molecular weight of approximately 50 , 000 to 60 , 000 , for example , and which does not substantially intrude into cells . Further, the macromolecular compound is preferably the one which does not cause denaturation or the
like of a biological material . Specific examples of the water- soluble macromolecular compound encompass a crosslinked sucro se macromolecular substance , polyethylene glycol, polyvinyl pyrrolidone , and Percoll (product name ; a macromolecular substance obtained by covering colloidal silica with a polyvinyl pyrrolidone film) . Specific examples of the crosslinked sucrose macromolecular substance encompass a macromolecular substance which is obtained by crosslinking (copolymerizing) sucrose with epichlorohydrin and which has a weight-average molecular weight of approximately 70 , 000 , such as Ficoll PM70 (product name) .
Unlike urea and a urea derivative , these water- soluble macromolecular compounds do not intrude into cells . Furthermore , these water- soluble macromolecular compounds are soluble in water. Therefore , these water- soluble macromolecular compounds are considered to contribute to controlling of an osmotic pressure difference between the inside and outside of a cell. As such, each of these water- soluble macromolecular compounds helps a biological material to be subj ected to a clearing treatment maintain its original shape , and particularly contributes to prevention of swelling of the biological material. In a case where the clearing reagent according to the present invention has a relatively high osmotic pre ssure , the clearing reagent preferably contains any of these water- soluble
macromolecular compounds . However, the present invention is not limited to this .
(Other Components)
A "clearing reagent for making a biological material transparent" according to the present invention can contain a "drying inhibition component" , which is at least one compound selected from glycerol, carboxy vinyl polymer, hydroxypropyl methylcellulose, propylene glycol, and macrogol, if necessary. The drying inhibition component prevents drying of a biological material subj ected to a clearing treatment. In particular, in a case where the biological material after the cleaning treatment may be kept waited for a long time period before an optical microscopic observation thereof, or in a case where an optical micro scopic observation of the biological material is time- consuming, the clearing reagent of the present invention preferably contains any of the above drying inhibition components .
Further, in addition to the above-described "urea and / or a urea derivative" , " surfactant" , and "water- soluble macromolecular compound" , a "clearing reagent for making a biological material transparent" according to the present invention may contain an additive(s) such as a pH adjusting agent and / or an osmotic pressure controlling agent, if necessary.
(Solvent)
A "clearing reagent for making a biological material transparent" according to the present invention is a solution containing a solvent in which urea is soluble . The solvent is not limited to any specific kind, as long as urea is soluble in the solvent. Preferably, water is used as a main solvent; particularly preferably, only water is used as the solvent. Note that, in the present invention, what is meant by the expression "water is used as a main solvent" is that a volumetric percentage of water to all solvents used is larger than that of any other solvent, and preferably that water is used in an amount which accounts for more than 50% and not more than 1 00% of a total volume of all solvents used . A "clearing reagent for making a biological material transparent" prepared by using water as a main solvent is referred to as a "clearing reagent for making a biological material transparent" as an aqueous solution .
In the case where water is used as a main solvent, the water may be mixed with dimethyl sulfoxide (DM SO) for application to a fixed sample, for example . It is expected that, for example , use of a mixture of DM SO and water to a fixed sample provide s effects such as (i) improvement in permeability of the clearing reagent with respect to a biological material and (ii) facilitation of a clearing treatment with re spect to a tissue having a keratin surface .
Main advantage s of the use of water as the solvent are as follows : 1 ) Urea, which is an active component of a "clearing reagent for making a biological material transparent" according to the pre sent invention, is excellent in resolvability in water; therefore, the use of water as the solvent makes it possible to prepare easily and at a low cost the clearing reagent for making a biological material transparent. 2) Compared with a case where an organic solvent is used as a main solvent, the use of water as the solvent does not involve dehydration of a biological material to be subjected to a clearing treatment; therefore, the use of water as the solvent can prevent the problem of shrinkage of a biological material. 3) Compared with a case where an organic solvent is used as a main solvent, the use of water as the solvent significantly reduces the possibility of damaging a fluorescent protein ; this makes it possible to observe , with use of a fluorescent protein, a biological material having been subj ected to a clearing treatment. 4) The use of water as the solvent makes it possible to apply the clearing reagent of the present invention not only to a clearing treatment on a fixed material but also to a clearing treatment on a living material . 5) The use of water as the solvent makes a clearing treatment reversible (described later) , that is , the use of water as the solvent can bring a biological material having been subj ected to a clearing
treatment back to a state that it had before the clearing treatment, if necessary. 6) Compared with a case where an organic solvent is used as a main solvent, the use of water as the solvent enhances safety in handling of the clearing reagent.
A "clearing reagent for making a biological material transparent" according to the present invention may be a buffer which can maintain a pH suitable for a biological material to be subj ected to a clearing treatment. Further, a "clearing reagent for making a biological material transparent" according to the present invention may have an osmotic pressure adjusted to a degree which does not cause deformation of a biological material to be subj ected to a clearing treatment and which allows urea to sufficiently penetrate into the biological material.
Note that, as with the case of urea, the above solvent can also be used for the urea derivative .
(Quantitative Relationship between Components)
The "clearing reagent for making a biological material transparent" according to the present invention is not particularly limited in terms of an amount of "urea" contained therein, as long as the clearing reagent with that amount of urea can proceed the clearing treatment on a biological material . Note that an upper limit of the amount of urea contained in the clearing reagent is determined by the
solubility of urea with respect to a solvent to be used. For example , a clearing reagent with a relatively small amount of urea can perform a required treatment by performing the treatment for a long time , while a clearing reagent with a relatively large amount of urea can perform a required treatment by performing the treatment for a short time , although this depends on the type of the biological material to be subj ected to the treatment. However, in order to enable a clearing treatment in various degrees , a concentration of urea in a clearing reagent of the present invention is preferably 1 M or more and not more than 8.5M , more preferably 3.5M or more and not more than 8.5M , particularly preferably 4M or more and not more than 8M . In the case where the urea derivative (or a mixture of urea and the urea derivative) is used instead of urea, an amount of the urea derivative (or the mixture) in the clearing agent can also be set to the same amount as that of urea.
In the case where a "surfactant" is used in a clearing reagent of the present invention, the clearing reagent is not particularly limited in terms of an amount of the surfactant contained therein . Preferably, the surfactant is contained therein at a concentration of 0.025 (w/ v) % or more and not more than 5 (w/ v)% , more preferably 0.05 (w/ v)% or more and not more than 0.5(w/ v) % , particularly preferably 0.05 (w/ v)% or more and not more than 0.2 (w/ v)% . Note that the unit
"(w/v)%" represents a percentage of a weight (w (gram)) of a surfactant used, with respect to a volume (v (milliliter)) of the clearing reagent.
In the case where a "water-soluble macromolecular compound" is used in a clearing reagent of the present invention, the clearing reagent is not particularly limited in terms of an amount of water-soluble macromolecular compound contained therein. Preferably, the water-soluble macromolecular compound is contained therein at a concentration of 2.5(w/v)% or more and not more than 40(w/v)%. Further, in view of a balance between a swelling prevention effect for a biological material and a refractive index of the biological material after the clearing treatment, the above concentration is more preferably 5(w/v)% or more and not more than 25(w/v)%, further more preferably 10(w/v)% or more and not more than 20(w/v)%, particularly preferably 10(w/v)% or more and not more than 15(w/v)%. Note that the unit "(w/v)%" represents a percentage of a weight (w (gram)) of the water-soluble macromolecular compound used, with respect to a volume (v (milliliter)) of the clearing reagent.
In the case where a "drying inhibition component" such as glycerol is used in a clearing reagent of the present invention, the clearing reagent is not particularly limited in terms of an amount of the drying inhibition component
contained therein. Preferably, the drying inhibition component is contained therein at a concentration of 2.5(w/v)% or more and not more than 20(w/v)%, more preferably 5(w/v)% or more and not more than 15(w/v)%, particularly preferably 8(w/v)% or more and not more than 12(w/v)%. Note that the unit (w/v)% represents a percentage of a weight (w (gram)) of the drying inhibition component used, with respect to a volume (v (milliliter)) of the clearing reagent.
(Subject Biological Material)
A biological material to be subjected to a clearing treatment using a "clearing reagent for making a biological material transparent" of the present invention is not limited to any specific kind. Preferably, the biological material is a material derived from a plant or an animal, more preferably a material derived from an animal such as the one selected from fish, amphibians, reptiles, birds, and mammals, particularly preferably a material derived from a mammal. The mammal is not limited to any specific kind, examples of which encompass: laboratory animals such as mice, rats, rabbits, guinea pigs, and primates except for humans; pet animals such as dogs and cats; farm animals such as cows and horses; and humans.
Alternatively, the biological material may be an individual itself (except for a living human individual).
Further alternatively, the biological material may be an organ, a tissue, or a cell taken from an individual of a multicellular organism. A "clearing reagent for making a biological material transparent" of the present invention has excellent ability to make a subject transparent; therefore, even if the biological material is a tissue or an organ (e.g., the whole of or part of a brain) derived from a multicellular animal or an individual itself (e.g., an embryo) of a multicellular animal which is not a human, the biological material can be subjected to a clearing treatment.
Further, the biological material may be either of (i) a material fixed for a telescopic observation and (ii) a non- fixed material. In a case of using a fixed material, the material is preferably immersed in, e.g., a 20(w/v)% sucrose- PBS solution adequately (e.g., for 24 hours or more) after being subjected to a fixing process. Furthermore, preferably, this material is embedded into an OCT compound and frozen by liquid nitrogen, thawed in PBS, and then fixed again by a 4(w/v)% PFA-PBS solution.
Specific examples of the biological material encompass: a biological tissue having a fluorescent chemical substance injected thereto; a biological tissue stained with a fluorescent chemical substance; a biological tissue having a fluorescent protein-expressed cell transplanted thereto; and a biological tissue taken from a genetically-modified animal
in which a fluore scent protein is expressed .
(Examples of Particularly Preferable Composition of Clearing Reagent for Biological Material)
The following will describe examples of a particularly preferable composition of a "clearing reagent for making a biological material transparent" according to the present invention. The following clearing reagents are quite suitable for a clearing treatment particularly on the whole of or part (e . g. , the hippocampus or the whole or part of the cerebrum) of the brain or an embryo of a mammal such as a mouse . Note that clearing reagents for making a biological material transparent used in Examples 1 to 9 (described later) also satisfied the following conditions of the below-described clearing reagents ( 1 ) to (4) :
• Clearing reagent ( 1 ) for making a biological material transparent:
An aqueous solution obtained by dissolving urea in water at a concentration of 4M or more and not more than 8M .
• Clearing reagent (2) for making a biological material transparent:
An aqueous solution obtained by dissolving, in water, (i) urea at a concentration of 4 M or more and not more than 8M , (ii) a nonionic surfactant (e . g. , Triton X- 100) at a concentration of 0.05 (w/ v) % or more and not more than
0.2(w/v)%, and (iii) a drying inhibition component (e.g., glycerol) at a concentration of 8(w/v)% or more and not more than 12(w/v)%.
• Clearing reagent (3) for making a biological material transparent:
An aqueous solution obtained by dissolving, in water, (i) urea at a concentration of 4M or more and not more than 8M, (ii) a nonionic surfactant (e.g., Triton X-100) at a concentration of 0.05(w/v)% or more and not more than 0.2(w/v)%, (iii) a drying inhibition component (e.g., glycerol) at a concentration of 8(w/v)% or more and not more than 12(w/v)%, and (iv) a water-soluble macromolecular compound (e.g., Ficoll) at a concentration of 5(w/v)% or more and not more than 25(w/v)%.
• Clearing reagent (4) for making a biological material transparent:
An aqueous solution obtained by dissolving, in water, (i) urea at a concentration of 4M or more and not more than 8M, (ii) a nonionic surfactant (e.g., Triton X-100) at a concentration of 0.05(w/v)% or more and not more than 0.2(w/v)%, and (iii) dimethyl sulfoxide (DMSO) at a concentration of 8(w/v)% or more and not more than 12(w/v)%.
In the case where the urea derivative (or a mixture of urea and the urea derivative) is used instead of urea, the
clearing reagents ( 1 ) through (4) may be prepared with the urea derivative (or the mixture) at the same concentration as the above-described concentration of urea.
(Preparation of Clearing Reagent for Making Biological Material Transparent)
A method for preparing a "clearing reagent for making a biological material transparent" according to the present invention includes dissolving, in a solvent, (i) "urea and / or a urea derivative" and (ii) a "surfactant" , a "water-soluble macromolecular compound" , a "drying inhibition component" , and / or the like, each of which is used if necessary. A procedure for dissolving or mixing the component(s) in the solvent is not particularly limited .
(Example of Method for Clearing Treatment Using Clearing Reagent for Making Biological Material Transparent)
A method for a clearing treatment on a biological material with use of a "clearing reagent for making a biological material transparent" according to the present invention includes a step (clearing treatment step) for causing the clearing reagent to permeate into the biological material. More specifically, this step causes the clearing reagent to permeate into the biological material in a container for a clearing treatment.
In the clearing treatment step, whether the clearing reagent or the biological material is stored in the container
for the clearing treatment first is not particularly limited . Preferably, the clearing reagent is stored in the container first, and subsequently the biological material is stored therein (i. e . , the biological material is put into the clearing reagent) .
A processing temperature at which the above clearing treatment step is performed is not particularly limited ; preferably, the processing temperature is within a range of 15°C or more and not more than 45°C . A processing time for which the clearing treatment is performed is not particularly limited ; preferably, the processing time is within a range of two hours or more and not more than six months , more preferably 12 hours or more and not more than seven days . A pressure at which the clearing treatment is performed is not particularly limited.
The container for the clearing treatment which is used in the above clearing treatment step and in which the biological material having been subj ected to the clearing treatment is stored may be preserved , e . g. , at room temperature or in a low-temperature environment until the container is used in the below-described observation step . (A step for preserving a sample after a clearing treatment)
(Step for Observation of Biological Material Having Been Subj ected to Clearing Treatment)
On the biological material having been subj ected to the
clearing treatment, an observation step by, e . g. , an optical micro scope is subsequently performed . On the biological material to be subj ected to the observation step, a visualizing treatment step (e . g. , staining or marking) may be performed (i) before the clearing treatment step or (ii) after the clearing treatment step but before the observation step , if nece ssary.
For example, in a case where the visualizing treatment step involves use of a fluorescent protein, a fluorescent protein gene is transferred into a living biological material before the clearing treatment step so that the fluorescent protein will be expressed therein.
In a case where the visualizing treatment step is (i) inj ection of a fluorescent chemical substance (which is not a fluorescent protein) into a biological material or (ii) staining of a biological material with a fluorescent chemical substance , the visualizing treatment step is preferably performed before the clearing treatment step . However, such the visualizing treatment step may be performed after the clearing treatment step . Alternatively, the visualizing treatment step may be staining of a biological material with a chemical substance which is not a fluorescent chemical substance .
The observation step can be performed with use of any type of optical microscope . For example , the observation step
can be performed by employing a three-dimensional super- resolution microscopy technique (e.g., STED, 3D PALM, FPALM, 3D STORM, or SIM). Preferably, the observation step is performed by employing a multi-photon excitation type (generally, two-photon excitation type) optical microscopy technique.
(Other Applications)
A clearing treatment using a "clearing reagent for making a biological material transparent" according to the present invention is reversible. As such, a biological material having been subjected to the clearing treatment can be brought back to a state that it had before the clearing treatment, e.g., by immersing the biological material in an equilibrium salt solution so as to remove therefrom the components of the clearing reagent. Here, specific examples of the equilibrium salt solution encompass: equilibrium salt solutions (e.g., PBS and HBSS) which are buffered by phosphate; an equilibrium salt solution (TBS) which is buffered by tris hydrochloride; an artificial cerebrospinal fluid (ACSF); and basal media for cell culturing, such as MEM, DMEM, and Ham's F-12.
The use of the clearing reagent does not cause denaturation or the like of a protein, etc. in the biological material, before and after the clearing treatment, or in a case where, after the clearing treatment, the biological
material is brought back to a state that it had before the clearing treatment. Accordingly, antigenicity of the protein, etc . in the biological material is preserved as unchanged . As such, for example, after a biological material is subj ected to a clearing treatment and an optical microscopic observation , the biological material can be brought back to a state that it had before the clearing treatment, so as to undergo , e . g. , a detailed assay by means of generally-used tissue staining or immuno staining.
(Kit for Clearing Treatment for Making Biological Material Transparent)
A "kit for a clearing treatment for making a biological material transparent" according to the present invention includes the above-described "clearing reagent for making a biological material transparent" . The "kit for a clearing treatment for making a biological material transparent" may further include at least one selected from : a "container for a clearing treatment" used in the clearing treatment step; a "biological material holding tool (e . g. , tweezers)" ; an "equilibrium salt solution" for bringing a biological material having been subj ected to a clearing treatment back to a state that it had before the clearing treatment; and an "instruction manual for the kit" .
(System for Clearing Treatment for Making Biological Material Transparent)
A system for a clearing treatment for making a biological material transparent according to the present invention includes : a "clearing reagent for making a biological material transparent" according to the present invention; and the above-described "biological material" which has been isolated . Further, in this system, the clearing reagent has permeated into the biological material so as to make the biological material transparent. That is , a concept of this system for a clearing treatment encompasses, e . g. , (i) a treatment system including a biological material which is in a midterm stage of a clearing treatment or (ii) a treatment system including a biological material on which a clearing treatment has been completed .
(Various Embodiments of the Present Invention)
As described above , a clearing reagent for making a biological material transparent according to the present invention includes, as an active component, at least one compound selected from the group consisting of urea and urea derivatives , the clearing reagent being a solution .
In the clearing reagent for making a biological material transparent according to the present invention, having the above arrangement, urea is more preferably contained as the active component.
The clearing reagent for making a biological material transparent according to the present invention , having the
above arrangement, is more preferably an aqueous solution.
The clearing reagent for making a biological material transparent according to the pre sent invention, having the above arrangement, more preferably include s a surfactant.
In the clearing reagent for making a biological material transparent according to the present invention, having the above arrangement, the surfactant is more preferably a nonionic surfactant.
In the clearing reagent for making a biological material transparent according to the present invention, having the above arrangement, the nonionic surfactant is more preferably at least one selected from the group consisting of Triton X (Registered Trademark) , Tween (Registered Trademark) , and NP-40 (product name) .
The clearing reagent for making a biological material transparent according to the present invention, having the above arrangement, more preferably includes a water- soluble macromolecular compound .
In the clearing reagent for making a biological material transparent according to the present invention, having the above arrangement, the water- soluble macromolecular compound is more preferably at least one selected from the group consisting of Percoll (Registered Trademark) , Ficoll (Registered Trademark) , polyethylene glycol, and polyvinyl pyrrolidone .
In the clearing reagent for making a biological material transparent according to the pre sent invention, having the above arrangement, the urea is more preferably contained at a concentration of 1 M or more and not more than 8.5M , the surfactant is more preferably contained at a concentration of 0.025 (w/ v)% or more and not more than 5 (w/ v) % , and the water-soluble macromolecular compound is more preferably contained at a concentration of 2.5 (w/ v)% or more and not more than 40 (w/ v)% .
The clearing reagent for making a biological material transparent according to the present invention more preferably further includes at least one selected from the group consisting of glycerol, carboxy vinyl polymer, hydroxypropyl methylcellulose, propylene glycol, and macrogol.
The clearing reagent for making a biological material transparent according to the present invention preferably makes transparent (i) a tissue or an organ derived from a multicellular animal or (ii) a multicellular animal which is not a human.
The present invention also provides a system for a clearing treatment for making a biological material transparent, including: any of the above clearing reagents ; and a biological material which has been isolated , the clearing reagent having permeated into the biological
material in order to make the biological material transparent.
A method according to the pre sent invention for making a biological material transparent includes the step of: causing any of the above clearing reagents to permeate into a biological material which has been isolated, in order that the biological material is made transparent.
A method according to the present invention for recovering a biological material having been made transparent by a clearing treatment include s the step of: causing an equilibrium salt solution to permeate into a biological material having been made transparent according to the above method, in order that the biological material is brought back to a state that the biological material had before the clearing treatment.
The present invention also provides a kit for a clearing treatment for making a biological material transparent, including any of the above clearing reagents .
[Examples]
The following will further specifically describe the present invention with reference to Examples, Comparative Examples, etc . below. However, the present invention is not limited to these .
[Example 1 : Observation of Hippocampus]
(Step for Perfusion Fixation)
A transgenic mouse having a fluorescent protein YFP
expressed in its neurons of the nervous system (YFP- H line : provided by Professor Jo sh Sanes of Harvard University, U . S .A. [reference] Feng et al. Neuron , 28 : 4 1 - 5 1 , 2000) of 7 to 8 week-old after birth was used . A peristaltic pump was used to perfuse an ice-cold PBS from the left cardiac ventricle of the mouse , and then to perfuse an ice-cold fixing solution (4% paraformaldehyde-PBS, pH 7.4) , so that the mouse was systemically fixed .
(Step for Taking-Out and Fixing of Biological Material)
Subsequently, the cranial bones were removed from the mouse , and the hippocampus was carefully taken out therefrom. Then, the hippocampus taken out was immersed in an ice-cold fixing solution (4% paraformaldehyde- PBS , pH 7.4) for one night at 4°C . Thereafter, the hippocampus was transferred into a 20% sucrose-PBS solution, and was then gently shaken for 24 hours at 4°C .
Next, after the hippocampal tissue was completely replaced by the 20% sucrose-PBS solution, the hippocampus was embedded into an OCT compound, and was then frozen by liquid nitrogen . Then , the frozen hippocampus was put into PBS , and was thawed at room temperature . The hippocampus thawed was refixed in a 4% paraformaldehyde- PBS for an hour.
(Step for Clearing Treatment and Observation of Biological Material)
Lastly, the refixed hippocampus was immersed in a clearing reagent according to the present example for making a biological material transparent and was shaken at room temperature for three days . The clearing reagent was an aqueous solution prepared by dissolving 4M urea in pure water. At the point when the clearing treatment had progressed (three days after the start of the treatment) , the hippocampus was embedded in agaro se gel (concentration: 0.5% (w/ v) or less) , and was observed from its bottom side to top surface side with use of an upright two-photon microscope (product name : FV 1000MPE, manufactured by Olympus Corporation) provided with a laser having a wavelength of 920 nm. Note that an obj ective lens used in the observation had a working distance of 2 mm .
The result of the observation is shown in Fig. 1 . As shown in Fig. 1 , performing the clearing treatment with use of the clearing reagent according to the present example could allow a clear observation of a range of approximately 1 .9 mm in depth (corresponding to the thickness of the biological material) , the range covering the dentate gyrus (DG) , the CA l , and the top surface of the hippocampus .
[Example 2 : Observation of Hippocampus and Study of Reagent]
A mouse hippocampus was observed according to the same method as that of Example 1 , except that (i) Example 2
used, as the clearing reagent used in the "Step for Clearing Treatment for Making Biological Material Transparent" , an aqueous solution (referred to as a SCALE-A2 reagent) prepared by dissolving, in pure water, 4M urea, 0. 1 %(w/ v) Triton X- 100 , and 10%(w/ v) glycerol and (ii) Example 2 performed an observation from the top surface side to the bottom side of the hippocampus.
The result of the observation is shown in Fig. 2. As shown in Fig. 2 , the clearing treatment with use of the clearing reagent according to the pre sent example could allow a clear observation of a range of approximately 2 mm in depth (corresponding to the thickness of the biological material) , the range covering the top surface , the CA 1 , the dentate gyrus (DG) , and the bottom of the hippocampus .
[Example 3 : Observation of Cerebrum]
A mouse cerebrum was observed according to the same method as that of Example 1 , except for the following points 1 ) to 3) :
1 ) In the "Step for Taking-Out and Fixing of Biological Material" of Example 3 , the whole of the cerebrum was taken out and fixed , and the cerebrum fixed was used as a biological material.
2) In the "Step for Clearing Treatment and Observation of Biological Material" of Example 3 , a SCALE-A2 reagent identical to the one used in Example 2 was used as a
clearing reagent for making a biological material transparent 3) In the "Step for Clearing Treatment and Observation of Biological Material" of Example 3 , an obj ective lens having a working distance of 3 mm was used to perform an observation from the cerebrum top surface (cerebral cortex) side to the hippocampus side .
The result of the observation is shown in Fig. 3. As shown in Fig, 3 , performing the clearing treatment with use of the clearing reagent according to the present example could allow a clear observation of a range of approximately 3 mm in depth (a working limit of the objective lens) , the range covering, of course, the cerebral cortex and the layer V-VI , and further covering the white matter region (corpus callosum) below the cerebral cortex, the fiber tract of the hippocampus, and even a cell group constituting the CA 1 of, the dentate gyrus (DG) , etc .
Note that conventional clearing reagents could not make transparent the white matter region below the cerebral cortex, and therefore did not allow an observation of a range deeper than the white matter region .
[Example 4 : Study of Reagent]
According to the conditions below, the following items were evaluated : (i) a degree to which a SCALE-A2 reagent swells a biological material; and (ii) an effect of swelling prevention measure using Ficoll together with a SCALE-A2
reagent.
1 ) First, a mouse cerebrum was subj ected to a clearing treatment with use of a SCALE-A2 reagent, according to the same method as that described in Example 3 except that the clearing treatment was carried out for two days . Then, a volume of the cerebrum having been subj ected to the clearing treatment was measured . Note that, the two-day clearing treatment was sufficient to make the mouse cerebrum transparent to a degree allowing an observation .
2) Mouse cerebra were subj ected to a clearing treatment in the same manner as in 1 ) , except that SCALE-A2 reagents respectively having 5% (w/ v) Ficoll and 20%(w/ v) Ficoll added thereto were used as a clearing reagent. Then, respective volumes of the cerebra having been subj ected to the clearing treatment were measured .
3) As a control, a mouse cerebrum was immersed in PB S , and a volume thereof was measured immediately after the immersion (0 day after the immersion) .
The result of the observation is shown in Fig. 4. Fig. 4 shows that, in comparison with the control (indicated as "PB S" in Fig. 4) , the cerebrum (indicated as "SCALE-A2" in Fig. 4) having been subj ected to the above treatment 1 ) swelled . Meanwhile , swelling of the cerebrum having been subjected to the above treatment 2) was reduced according to the amounts of Ficoll added. In particular, the use of the
clearing reagent having 20% (w/ v) Ficoll added thereto reduced the swelling by 85% or more (indicated as "SCALE- A2 + 20% Ficoll" in Fig. 4) .
The cerebrum which has not swelled or retracted is particularly preferable; however, the cerebrum which has swelled or retracted can also be observable as a sample by an optical micro scope .
[Example 5]
A mouse cerebrum was observed according to the same method as that of Example 1 except for the following points 1 ) and 2) :
1 ) In the "Step for Clearing Treatment and Observation of Biological Material" of Example 5 , a clearing reagent for making a biological material transparent was an aqueous solution prepared by dissolving, in pure water, 4M urea, 0. 1 %(w/ v) Triton X- 100 , 1 0%(w/ v) glycerol, and 10%(w/ v) Ficoll, and a clearing treatment was performed for three days .
2) In the "Step for Clearing Treatment and Observation of Biological Material" of Example 5 , an obj ective lens having a working distance of 2 mm was used to perform an observation from the cerebrum top surface (cerebral cortex) side to the hippocampus side .
The result of the observation is shown in Fig. 5. As shown in Fig. 5 , the clearing treatment with use of the clearing reagent according to the present example could
allow a clear observation of a range of approximately 2.16 mm in depth (a working limit of the objective lens), the range covering, of course, the cerebral cortex and the layer V-VI, and further covering the white matter region (corpus callosum) below the cerebral cortex, the fiber tract of the hippocampus, and even a cell group constituting the CA1, etc.
Note that conventional clearing reagents could not make transparent the white matter region below the cerebral cortex, and therefore did not allow an observation of a range deeper than the white matter region.
[Example 6: Evaluation of Light Transmittance]
Mouse brain slices (thickness: 60 micrometer) were treated for one day with (i) water, (ii) PBS, (iii) an 8M urea aqueous solution (clearing reagent), (iv) a 4M urea aqueous solution (clearing reagent), (v) a clearing reagent SCALE-A2 (an aqueous solution containing 4M urea, 0.1%(w/v) Triton X-100, and 10%(w/v) glycerol), and (vi) a clearing reagent SCALE-D2 (an aqueous solution containing 4M urea + 0.1%(w/v) Triton X-100 and 10%(w/v) DMSO), respectively. Then, a transmittance of a cerebral cortex portion of each mouse brain slice with respect to light having a wavelength of 200 nm to 1000 nm was measured. Note that a light wavelength band from 200 nm to 1000 nm covers both of (i) an excitation wavelength range commonly used in a two-
photon microscopic observation and (ii) a range of a main fluorescence wavelength of a fluorescent protein to be observed.
Note that the light transmittance measurement was performed with use of multichannel detector PMA-2 (Hamamatsu Photonics K.K.). The result of the measurement is shown in Fig. 6. As shown in Fig. 6, light transmittances of the samples respectively treated with the 8M urea aqueous solution, the 4M urea aqueous solution, the clearing reagent SCALE-A2, and the clearing reagent SCALE- D2 were each 80% or more. That is, these samples exhibited outstanding effects of the clearing treatment, unlike the samples treated with water or PBS.
[Example 7: Clearing Treatment for Making Mouse Fetus Transparent]
A Fucci-S-Green (Fucci-S/G2/M)-expressed transgenic mouse fetus at 13.5 days of fetal life (obtained by breeding of mice produced by Laboratory for Cell Function Dynamics, Brain Science Institute, RIKEN [reference: Sakaue-Sawano et al., Cell, 132(3): 487-98, 2008.]) was fixed with 4(w/v)% PFA-PBS for two days, and was then immersed in a 20(w/v)% sucrose-PBS solution. Thereafter, the fetus was frozen once, and was then thawed. After that, the fetus was fixed again with 4(w/v)% PFA-PBS for an hour. Subsequently, the fetus was immersed in SCALE-A2 described in Example 2 for seven
days for a clearing treatment.
Next, the fetus was embedded in agarose gel (concentration: 0.5%(w/v) or less), and was observed with use of a fluorescent stereomicroscope (product name: MZ10F, manufactured by Leica Microsystems). Note that an objective lens used in the observation had a working distance of 70 mm.
The result of the observation is shown in Fig. 7. As shown in Fig. 7, by performing the clearing treatment with use of the clearing reagent according to the present example, the whole body of the mouse fetus was made transparent outstandingly, although only the liver thereof had a small yellow portion left. Note that the mounting rubber (mr) shown in Fig. 7 was used to support the head of the mouse fetus.
[Example 8: Observation of Neural Progenitor Cells in Mouse Hippocampus]
(Step for Perfusion Fixation)
A Fucci-S-Green (Fucci-S/G2/ M)-expressed transgenic mouse of six week-old after birth (obtained by breeding of mice produced by Laboratory for Cell Function Dynamics, Brain Science Institute, RIKEN [reference] Sakaue-Sawano et al., Cell, 132(3): 487-98, 2008.) was used. A peristaltic pump was used to perfuse an ice-cold PBS from the left cardiac ventricle of the mouse, and then to perfuse an ice-
cold fixing solution (4% paraformaldehyde- PBS , pH 7.4) , so that the mouse was fixed systemically .
(Step for Taking-Out and Fixing of Biological Material)
Subsequently, the cranial bone was removed from the mouse , and the dentate gyrus of hippocampus was carefully taken out therefrom. Then , the dentate gyrus of hippocampus taken out was immersed in an ice-cold fixing solution (4% paraformaldehyde- PBS , pH 7.4) for one night at 4°C . Thereafter, the dentate gyrus of hippocampus was transferred into a 20% sucrose-PBS solution, and was then gently shaken for 24 hours at 4°C .
Next, after the dentate gyrus of hippocampus was completely replaced by the 20% sucrose-PB S solution, the dentate gyrus of hippocampus was embedded into an OCT compound, and was then frozen by liquid nitrogen . Then , the dentate gyrus of hippocampus frozen was put into PBS , and was thawed at room temperature . The dentate gyrus of hippocampus unfrozen was refixed in a 4% paraformaldehyde-PBS for an hour.
Note that the blood vessels of the dentate gyrus used in the present example were stained with Lectin-Texas Red conjugate .
(Step for Clearing Treatment and Observation of Biological Material)
Lastly, the dentate gyrus of hippocampus refixed was
immersed for three days in a clearing reagent according to the present example for making a biological material transparent, and was shaken at room temperature. The clearing reagent was an aqueous solution prepared by dissolving, in pure water, 4M urea, 0.1%(w/v) Triton X-100, and 10%(w/v) glycerol. At the point when the clearing treatment had progressed (three days after the start of the treatment), the dentate gyrus of hippocampus was embedded in agarose gel (concentration: 0.5%(w/v) or less), and was observed with use of an upright two-photon microscope (product name: FV1000MPE, manufactured by Olympus Corporation) provided with a laser having a wavelength of 920 nm. Note that an objective lens used in the observation had a working distance of 2 mm. The observation was performed on 18 consecutive visual fields, from the ventral side of the hippocampus to 1.7 mm-depth. Then, the results of the observation were combined into an integrated image.
The result of the observation is shown in Fig. 8. As shown in Fig. 8, it was confirmed that the clearing treatment with use of the clearing reagent according to the present example allowed to observe that Fucci-S-Green (Fucci- S/ G2/ M)-positive neural progenitor cells existed around the blood vessels.
[Example 9: Observation Regarding Transplantation of Neural Progenitor Cells]
Neural progenitor cells derived from the hippocampus of a fluorescent protein Venus-expressed adult rat were obtained . Then, the neural progenitor cells obtained were transplanted into a cerebral cortex portion (in the vicinity of the layer V, approximately 1 .7 mm in depth) of a Fischer F344- strain rat (purchased from Japan SLC , Inc . ) .
Three days after the transplantation of the neural progenitor cells , the Fischer F344- strain rat was fixed according to the method described in the (Step for Perfusion Fixation) of Example 8. Subsequently, according to the method described in the (Step for Taking-Out and Fixing of Biological Material) of Example 8 , the cerebral cortex of the Fischer F344- strain rat was fixed. Note that the blood vessels of the rat cerebral cortex used in the present example were stained with Lectin-Texas Red conjugate .
Subsequently, according to the method described in the (Step for Clearing Treatment and Observation of Biological Material) of Example 8 , the cerebral cortex was observed . The result of the observation is shown in Fig. 1 1 . As shown in Fig. 1 1 , performing the clearing treatment with use of the clearing reagent according to the present example allowed to observe that fluorescence protein Venus-expressed neural progenitor cells had gathered in the vicinity of the blood vessels (stained with Lectin Texas-Red conjugate) . Thus , the pre sent method is suitable for an observation of movement of
cells after transplantation, changes in the morphology, and the like.
[Comparative Example 1: Comparison with BABB Method (1)]
Transgenic mice each having a fluorescent protein YFP expressed in its nervous system (YFP-H line: provided by Professor Josh Sanes of Harvard University, U.S.A. [reference] Feng et al. Neuron, 28: 41-51, 2000) of 12 week- old after birth were used. From the mice, the cerebra were taken out. Then, a clearing treatment using a SCALE-A2 reagent (the present invention: see Example 2) was compared with a clearing treatment according to a benzylbenzoate/benzylalchol (BABB) method described by Dodt et al. in Non-Patent Literature 2.
Each of the clearing treatments was performed in such a manner that the cerebrum was immersed in the clearing treatment solution for two days. The clearing treatment solution used in the BABB method was composed of benzylalchol and benzylbenzoate (composition ratio therebetween = 1:2).
The results are shown in Fig. 9. In Fig. 9, upper portions of the respective columns indicated as "Transmission" and "YFP" show the results of the treatment using the SCALE-A2 reagent, whereas lower portions thereof show the results of the treatment according to the BABB
method. Note that the column "Transmission" shows the result of the observation with use of a transmission microscope, whereas the column "YFP" shows the result of the observation of fluorescence from YFP with use of a fluorescence microscope.
As shown in Fig. 9, with the clearing treatment using the SCALE-A2 reagent, it was possible to clearly observe fluorescence emitted by YFP. On the other hand, with the clearing treatment according to the BABB method, the cerebrum was crucially shrunk, and fluorescence from YFP decayed significantly.
[Comparative Example 2: Comparison with BABB Method (2)]
Genes encoding various fluorescent proteins were respectively transferred into HeLa cells (provided by The Institute of Medical Science, The University of Tokyo; Scherer et al., J. Exp. Med. 97(5) :695-710, 1953) so that the corresponding fluorescent proteins were expressed therein. The fluorescent proteins expressed were SECFP, EGFP, mAGl, Venus, and DsRed (license of use of EGFP and DsRed was obtained from Clontech Laboratories, Inc.; license of use of mAGl was obtained from Medical & Biological Laboratories Co., Ltd.; Venus and SECFP were produced by introduction of genetic mutation based on GFP, by Laboratory for Cell Function Dynamics, Brain Science
Institute, RIKEN. [Reference] SECFP, Hadjantonakis et al., BMC BiotechnoL, 2:11, 2002.: EGFP, Zhang et al. Biochem. Biophys. Res. Commun., 227: 707-711, 1996.: Venus, Nagai et al., Nat. Botech., 20: 87-90, 2002.: mAG 1 , Karasawa et al., J. Biol. Chem., 278(36): 34167-34171, 2003.: Baird et al., PNAS., 97(22): 11984-11989, 2000.).
Subsequently, in the same manner as in Comparative Example 1, a clearing treatment using a SCALE-A2 reagent (see Example 2) and a clearing treatment according to the benzylbenzoate/benzylalchol (BABB) method described by Dodt et al. in Non-Patent Literature 2 were performed, and these two treatments were compared with each other.
The result of the observation is shown in Fig. 10. Fig. 10 shows a relative value of a fluorescence intensity from a fluorescent protein after a clearing treatment, with respect to a fluorescence intensity (= 100) from the fluorescent protein before the clearing treatment. As is clear from Fig. 10, in each case, the clearing treatment using the SCALE-A2 reagent (the present invention: see Example 2) maintained 80% or more of the fluorescence intensity from the fluorescent protein. On the other hand, in each case, the clearing treatment according to the BABB method caused a significant reduction in the fluorescence intensity from the fluorescent protein.
[Example 10: Recovery of Tissue after Clearing
Treatment]
From the hippocampuses of a GFP transgenic mouse and a YFP transgenic mouse (GFP-M line and YFP- H line , provided by Professor Josh Sanes of Harvard University, U . S .A. ) , 2.5 mm-thickness slices were prepared . Then , these slices were subj ected to a clearing treatment using a SCALE- A2 reagent (see Example 2) for five days so that the slices were made transparent once . Thereafter, the slice s were rinsed with PBS three times so that the tissues in the slices were brought back to a non-transparent state . The slice s in the non-transparent state were compared with slices having not been subj ected to a clearing treatment using a SCALE-A2 reagent, in terms of immunostaining properties .
The immunostaining was performed as follows : As a primary antibody, (i) mouse-derived anti-polysialilated neural cell adhesion molecule (PSA-NCAM) monoclonal antibody (Millipore Corporation) that recognizes a polysialic acid of PSA-NCAM existing on a surface of an immature neuronal cell and (ii) rabbit-derived anti-glial fibrillary acidic protein (GFAP) polyclonal antibody (Sigma-Aldrich) that recognizes an intermediate filament GFAP specific to astroglia were used, and were caused to react with their respective target proteins in the slices for 24 hours at 4°C . Thereafter, the slices were rinsed with PBS . Then , the anti- PSA- NCAM monoclonal antibody was caused to react with an
Alexa Fluor 546-labeled anti-mouse IgM antibody (Invitrogen, Molecular Probes) , which was used as a secondary antibody, at room temperature for three hours; and the GFAP polyclonal antibody was caused to react with an Alexa Fluor 633 -labeled anti-rabbit IgG antibody (Invitrogen, Molecular Probe s) , which was used as a secondary antibody, at room temperature for three hours . In this manner, the slices were immunohistochemically stained. Since fluorescence from these slices did not decayed, triple fluorescent (fluorescence including GFP and YFP) stained images were obtained . The observation was performed with a 20-power obj ective lens (UplanApo20 , Olympus Corporation) with use of an inverted confocal laser micro scope (FV500, Olympus Corporation) .
As shown in Fig. 12 , both before ("Before SCALE" in Fig. 12) and after ("After Recovery" in Fig. 12) the treatment using SCALE-A2 , (i) immature neurons existing in the dentate gyrus of hippocampus and (ii) mossy fibers extending from the immature neurons to the CA3 region were stained with the anti-PSA-NCAM monoclonal antibody with substantially no problem. Similarly, the astroglia was also stained with the anti-GFAP polyclonal antibody without any problem .
The present invention is not limited to the description of the embodiments and examples above , but may be altered by a skilled person within the scope of the claims . An
embodiment based on a proper combination of technical means disclosed in different embodiments is encompassed in the technical scope of the present invention.
Industrial Applicability
The present invention provides : a novel clearing reagent for making a biological material transparent which clearing reagent contains , as an active component, a component having a higher bio-affinity; and use thereof.
Claims
Claims
Claim 1
A clearing reagent for making a biological material transparent, comprising:
as an active component, at least one compound selected from the group consisting of urea and urea derivatives ,
the clearing reagent being a solution .
Claim 2
The clearing reagent as set forth in claim 1 , wherein: urea is contained as the active component.
Claim 3
The clearing reagent as set forth in claim 1 or 2 , wherein the clearing reagent is an aqueous solution .
Claim 4
The clearing reagent as set forth in any one of claims 1 through 3 , further comprising a surfactant.
Claim 5
The clearing reagent as set forth in claim 4 , wherein : the surfactant is a nonionic surfactant.
Claim 6
The clearing reagent as set forth in claim 5, wherein: the nonionic surfactant is at least one selected from the group consisting of Triton X (Registered Trademark), Tween (Registered Trademark), and NP-40 (product name).
Claim 7
The clearing reagent as set forth in any one of claims 3 through 6, further comprising a water-soluble macromolecular compound.
Claim 8
The clearing reagent as set forth in claim 7, wherein: the water-soluble macromolecular compound is at least one selected from the group consisting of Percoll (Registered Trademark), Ficoll (Registered Trademark), polyethylene glycol, and polyvinyl pyrrolidone.
Claim 9
The clearing reagent as set forth in claim 8, wherein: the urea is contained at a concentration of 1M or more and not more than 8.5M, the surfactant is contained at a concentration of 0.025(w/v)% or more and not more than 5(w/v)%, and the water-soluble macromolecular compound is contained at a concentration of 2.5(w/v)% or more and not more than 40(w/v)%.
Claim 10
The clearing reagent as set forth in any one of claims 1 through 9 , further comprising:
at least one selected from the group consisting of glycerol, carboxy vinyl polymer, hydroxypropyl methylcellulose, propylene glycol, and macrogol .
Claim 1 1
The clearing reagent as set forth in any one of claims 1 through 10 , wherein :
the clearing reagent make s transparent (i) a tissue or an organ derived from a multicellular animal or (ii) a multicellular animal which is not a human.
Claim 12
A system for a clearing treatment for making a biological material transparent, comprising:
a clearing reagent as set forth in any one of claims 1 through 10 ; and
a biological material which has been isolated,
the clearing reagent having permeated into the biological material in order to make the biological material transparent.
Claim 1 3
A method for making a biological mate rial transparent, comprising the step of:
causing a clearing reagent as set forth in any one of claims 1 through 1 0 to permeate into a biological material which has been isolated, in order that the biological material is made transparent.
Claim 1 4
A method for recovering a biological material having been made transparent by a clearing treatment, comprising the step of:
causing an equilibrium salt solution to permeate into a biological material having been made transparent according to a method as set forth in claim 1 3 , in order that the biological material is brought back to a state that the biological material had before the clearing treatment.
Claim 1 5
A kit for a clearing treatment for making a biological material transparent, comprising:
a clearing reagent as set forth in any one of claims 1 through 1 0.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/583,548 US20130045503A1 (en) | 2010-03-12 | 2011-03-11 | Clearing reagent for biological material, and use thereof |
| JP2012556745A JP5858435B2 (en) | 2010-03-12 | 2011-03-11 | Clarification reagent for biological materials and use thereof |
| EP11753531.0A EP2547999B1 (en) | 2010-03-12 | 2011-03-11 | Clearing reagent for biological material, and use thereof |
| CN2011800133544A CN102859344A (en) | 2010-03-12 | 2011-03-11 | Clearing reagent for biological material, and use thereof |
| US17/128,654 US20210131926A1 (en) | 2010-03-12 | 2020-12-21 | Clearing reagent for biological material, and use thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010-056709 | 2010-03-12 | ||
| JP2010056709 | 2010-03-12 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/583,548 A-371-Of-International US20130045503A1 (en) | 2010-03-12 | 2011-03-11 | Clearing reagent for biological material, and use thereof |
| US17/128,654 Division US20210131926A1 (en) | 2010-03-12 | 2020-12-21 | Clearing reagent for biological material, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011111876A1 true WO2011111876A1 (en) | 2011-09-15 |
Family
ID=44563665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2011/056502 WO2011111876A1 (en) | 2010-03-12 | 2011-03-11 | Clearing reagent for biological material, and use thereof |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20130045503A1 (en) |
| EP (1) | EP2547999B1 (en) |
| JP (1) | JP5858435B2 (en) |
| CN (2) | CN102859344A (en) |
| WO (1) | WO2011111876A1 (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013191274A1 (en) * | 2012-06-22 | 2013-12-27 | 独立行政法人理化学研究所 | Method for rendering biological material transparent and processing kit for rendering biological material transparent |
| CN103492852A (en) * | 2011-04-28 | 2014-01-01 | 独立行政法人理化学研究所 | Method for making biological material transparent and use thereof |
| WO2014010633A1 (en) | 2012-07-10 | 2014-01-16 | 独立行政法人理化学研究所 | Antibody composition, kit for preparing antibody composition, and immunostaining method |
| WO2014115206A1 (en) * | 2013-01-28 | 2014-07-31 | 独立行政法人科学技術振興機構 | Method for rendering tissue transparent, reagent for rendering tissue transparent, and tissue observation method |
| JP2015533210A (en) * | 2012-08-09 | 2015-11-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Methods and compositions for preparing biological specimens for microanalysis |
| WO2016117614A1 (en) * | 2015-01-20 | 2016-07-28 | 国立研究開発法人理化学研究所 | Biological-specimen transparentizing agent, system, and use therefor |
| EP2926658A4 (en) * | 2012-10-30 | 2016-08-31 | Kanazawa Medical University | Kit for producing transparentized biological specimen, and method for producing transparentized biological specimen |
| US20160266016A1 (en) | 2013-08-14 | 2016-09-15 | Riken | Composition for preparing biomaterial with excellent light-transmitting property, and use thereof |
| WO2017093323A1 (en) | 2015-12-01 | 2017-06-08 | Universität Duisburg-Essen | Non-hazardous optical clearing of biological samples |
| US20180306687A1 (en) * | 2017-04-21 | 2018-10-25 | Korea Research Institute Of Chemical Technology | Composition for clearing of biotissue and clarity method for biotissue using thereof |
| US10444124B2 (en) | 2011-05-20 | 2019-10-15 | Riken | Clarifying reagent for biological materials and use thereof |
| US10746981B2 (en) | 2014-05-30 | 2020-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging large intact tissue samples |
| US11022528B2 (en) | 2017-04-21 | 2021-06-01 | Korea Research Institute Of Chemical Technology | Composition for biological tissue transparency and method for biological tissue transparency using same |
| US11254974B2 (en) | 2016-02-10 | 2022-02-22 | The Board Of Trustees Of The Leland Stanford Junior University | RNA fixation and detection in clarity-based hydrogel tissue |
| US11365213B2 (en) | 2018-02-05 | 2022-06-21 | Korea Research Institute Of Chemical Technology | Composition for clearing spheroids, method for clearing spheroids using same, and kit comprising same |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10309879B2 (en) | 2014-02-21 | 2019-06-04 | Massachusetts Institute Of Technology | Expansion microscopy |
| CN106662511B (en) * | 2014-07-07 | 2020-05-22 | 林志勇 | Tissue clearing solution and use thereof |
| US10571371B2 (en) * | 2014-08-07 | 2020-02-25 | Wake Forest University Health Sciences | Compositions and methods for clearing a biological sample |
| JP6781421B2 (en) * | 2015-03-18 | 2020-11-04 | 国立研究開発法人理化学研究所 | Observation method and transparency method of biomaterials |
| US11408890B2 (en) | 2015-04-14 | 2022-08-09 | Massachusetts Institute Of Technology | Iterative expansion microscopy |
| US10059990B2 (en) | 2015-04-14 | 2018-08-28 | Massachusetts Institute Of Technology | In situ nucleic acid sequencing of expanded biological samples |
| US10526649B2 (en) | 2015-04-14 | 2020-01-07 | Massachusetts Institute Of Technology | Augmenting in situ nucleic acid sequencing of expanded biological samples with in vitro sequence information |
| CA2994958C (en) | 2015-08-07 | 2024-02-13 | Massachusetts Institute Of Technology | Nanoscale imaging of proteins and nucleic acids via expansion microscopy |
| CN108139408B (en) | 2015-08-07 | 2020-08-28 | 麻省理工学院 | Protein retention expansion microscopy |
| WO2017188264A1 (en) * | 2016-04-28 | 2017-11-02 | 国立研究開発法人理化学研究所 | Composition for preparing biological material having excellent light transmissivity and use of composition |
| KR101866249B1 (en) * | 2016-11-29 | 2018-06-12 | 박순현 | Composition for clrearing of biotissue and clarity method for biotissue using thereof |
| CN106769298B (en) * | 2016-12-12 | 2019-04-16 | 中国科学院植物研究所 | A kind of microscopy observation method of plant tissue |
| CN110139922B (en) * | 2016-12-22 | 2021-05-25 | 香港大学 | Compositions and methods for clarifying tissue |
| US10995361B2 (en) | 2017-01-23 | 2021-05-04 | Massachusetts Institute Of Technology | Multiplexed signal amplified FISH via splinted ligation amplification and sequencing |
| CN108445206B (en) * | 2017-02-16 | 2021-01-01 | 中国科学院合肥物质科学研究院 | Biological tissue and organ transparentizing treatment liquid, treatment method and immune labeling method |
| WO2018157074A1 (en) | 2017-02-24 | 2018-08-30 | Massachusetts Institute Of Technology | Methods for diagnosing neoplastic lesions |
| WO2018157048A1 (en) | 2017-02-24 | 2018-08-30 | Massachusetts Institute Of Technology | Methods for examining podocyte foot processes in human renal samples using conventional optical microscopy |
| US11180804B2 (en) | 2017-07-25 | 2021-11-23 | Massachusetts Institute Of Technology | In situ ATAC sequencing |
| KR101849698B1 (en) * | 2017-08-24 | 2018-04-18 | 한국화학연구원 | Composition for controling a biotissue size and method for controling the biotissue size using the same |
| JP7028979B2 (en) * | 2017-12-29 | 2022-03-02 | エフ．ホフマン－ラ ロシュ アーゲー | Tissue sample preparation system |
| KR102354092B1 (en) * | 2018-02-05 | 2022-01-21 | 한국화학연구원 | Composition for clrearing of spheroid, clarity method for spheroid using the same and kit having the same |
| WO2019156957A1 (en) | 2018-02-06 | 2019-08-15 | Massachusetts Institute Of Technology | Swellable and structurally homogenous hydrogels and methods of use thereof |
| CN110763661B (en) * | 2018-07-25 | 2022-03-22 | 中国科学院合肥物质科学研究院 | Treatment fluid composition, kit and method for performing immunological labeling while transparentizing biological organ |
| CN109406768B (en) * | 2018-11-06 | 2023-01-24 | 扬州大学 | Method for observing three-dimensional distribution of cells in micro tissue and counting cell number |
| CN114402060A (en) * | 2019-07-08 | 2022-04-26 | 香港大学 | Compositions and methods for tissue clearing |
| EP4001888B1 (en) * | 2019-08-30 | 2023-10-04 | Cubicstars, Inc. | Biological tissue staining reagent, biological tissue staining kit and biological tissue staining method |
| US11802822B2 (en) | 2019-12-05 | 2023-10-31 | Massachusetts Institute Of Technology | Multiplexed expansion (MultiExM) pathology |
| KR102477568B1 (en) * | 2020-06-16 | 2022-12-15 | 서울대학교산학협력단 | A method of pretreatment of transparency of a biological samples with a size of 1 mm or less and a method of transparency of the biological samples comprising the same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000509146A (en) * | 1996-04-12 | 2000-07-18 | オンコール，インコーポレーテッド | Methods and compositions for controlling formaldehyde fixation by delayed quenching |
| JP2003517601A (en) * | 1999-12-14 | 2003-05-27 | ユニバーシティー・オブ・マイアミ | Rapid tissue processor |
| JP2007051957A (en) * | 2005-08-18 | 2007-03-01 | Shimadzu Corp | Direct mass spectrometry of living tissue |
| JP2008161138A (en) * | 2006-12-28 | 2008-07-17 | Sysmex Corp | Antigen activation liquid, antigen activation method and method for detecting cell |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4578282A (en) * | 1982-02-04 | 1986-03-25 | Harrison James S | Composition for diagnostic reagents |
| US4493821A (en) * | 1982-02-04 | 1985-01-15 | Harrison James S | Preservative and fixative preparations for biological systems |
| FR2599149B1 (en) * | 1986-05-21 | 1988-08-26 | Univ Nancy | REAGENT FOR TRANSPARIZING BIOLOGICAL MEDIA AND ITS ANALYTICAL APPLICATIONS. |
| US6793890B2 (en) * | 1997-08-20 | 2004-09-21 | The University Of Miami | Rapid tissue processor |
| US6232092B1 (en) * | 1998-10-02 | 2001-05-15 | Rogers Imaging Corporation | Method for preparing biological specimens for visual analysis |
| US6472216B1 (en) * | 2001-07-24 | 2002-10-29 | Ann-Shyn Chiang | Aqueous tissue clearing solution |
| MXPA04008776A (en) * | 2002-03-14 | 2005-04-19 | Vitreo Retinal Technologies In | Agents for corneal or intrastromal administration to treat or prevent disorders of the eye. |
| WO2007061783A1 (en) * | 2005-11-18 | 2007-05-31 | Trustees Of Boston University | Treatment and prevention of bone loss using resolvins |
| US20090191138A1 (en) * | 2008-01-30 | 2009-07-30 | Mediquest Therapeutics, Inc. | Novel topical formulations for improving the appearance of nails |
| GB0812999D0 (en) * | 2008-07-16 | 2008-08-20 | Blood Analysis Ltd | Detection of microorganisms |
| US20110123979A1 (en) * | 2008-07-16 | 2011-05-26 | Peter Salmon | Detection of microorganisms |
-
2011
- 2011-03-11 CN CN2011800133544A patent/CN102859344A/en active Pending
- 2011-03-11 CN CN201810150257.3A patent/CN108061677B/en active Active
- 2011-03-11 WO PCT/JP2011/056502 patent/WO2011111876A1/en active Application Filing
- 2011-03-11 EP EP11753531.0A patent/EP2547999B1/en active Active
- 2011-03-11 US US13/583,548 patent/US20130045503A1/en not_active Abandoned
- 2011-03-11 JP JP2012556745A patent/JP5858435B2/en active Active
-
2020
- 2020-12-21 US US17/128,654 patent/US20210131926A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000509146A (en) * | 1996-04-12 | 2000-07-18 | オンコール，インコーポレーテッド | Methods and compositions for controlling formaldehyde fixation by delayed quenching |
| JP2003517601A (en) * | 1999-12-14 | 2003-05-27 | ユニバーシティー・オブ・マイアミ | Rapid tissue processor |
| JP2007051957A (en) * | 2005-08-18 | 2007-03-01 | Shimadzu Corp | Direct mass spectrometry of living tissue |
| JP2008161138A (en) * | 2006-12-28 | 2008-07-17 | Sysmex Corp | Antigen activation liquid, antigen activation method and method for detecting cell |
Non-Patent Citations (3)
| Title |
|---|
| ATUSHI KYUMA ET AL.: "Histochemical Studies on Glycoconjugates in the Salivary Gland Connective Tissues of Laboratory Animals", JOURNAL OF NAGOYA CITY UNIVERSITY MEDICAL SCHOOL, vol. 42, no. 2, May 1991 (1991-05-01), pages 183 - 208, XP008166606 * |
| HIROYUKI HONMA: "A Study of the Vascular Network of Sciatic Nerves in Experimental Chronic Diabetic Rat.", JOURNAL OF ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE HOSPITAL, vol. 27, no. 4, 1 August 1999 (1999-08-01), pages 339 - 347, XP008166607 * |
| TAKANORI SAKAGAMI ET AL.: "Effects of treatment with urea upon the electron microscopic histochemical reactions of acidic glycoconjugates in fixed tissues.", CONNECT TISSUE, vol. 21, no. 2, November 1989 (1989-11-01), pages 37 - 38, XP008166605 * |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103492852A (en) * | 2011-04-28 | 2014-01-01 | 独立行政法人理化学研究所 | Method for making biological material transparent and use thereof |
| EP2703801A1 (en) * | 2011-04-28 | 2014-03-05 | Riken | Method for making biological material transparent and use thereof |
| EP2703801A4 (en) * | 2011-04-28 | 2014-09-17 | Riken | Method for making biological material transparent and use thereof |
| CN103492852B (en) * | 2011-04-28 | 2016-08-17 | 独立行政法人理化学研究所 | The transparence method of biomaterial and utilization thereof |
| US10444124B2 (en) | 2011-05-20 | 2019-10-15 | Riken | Clarifying reagent for biological materials and use thereof |
| US9933342B2 (en) | 2012-06-22 | 2018-04-03 | Riken | Method for rendering biological material transparent and processing kit for rendering biological material transparent |
| JP2014005231A (en) * | 2012-06-22 | 2014-01-16 | Institute Of Physical & Chemical Research | Method for making biological material transparent and kit for clearing treatment for making biological material transparent |
| US10883903B2 (en) | 2012-06-22 | 2021-01-05 | Riken | Method for rendering biological material transparent and processing kit for rendering biological material transparent |
| WO2013191274A1 (en) * | 2012-06-22 | 2013-12-27 | 独立行政法人理化学研究所 | Method for rendering biological material transparent and processing kit for rendering biological material transparent |
| WO2014010633A1 (en) | 2012-07-10 | 2014-01-16 | 独立行政法人理化学研究所 | Antibody composition, kit for preparing antibody composition, and immunostaining method |
| US10545075B2 (en) | 2012-08-09 | 2020-01-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for preparing biological specimens for microscopic analysis |
| JP2015533210A (en) * | 2012-08-09 | 2015-11-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Methods and compositions for preparing biological specimens for microanalysis |
| US11035763B2 (en) | 2012-10-30 | 2021-06-15 | Kanazawa Medical University | Kit for producing cleared biological specimens and method for producing cleared biological specimens |
| JPWO2014069519A1 (en) * | 2012-10-30 | 2016-09-08 | 学校法人金沢医科大学 | Clarified biological specimen preparation kit and transparent biological specimen preparation method |
| EP2926658A4 (en) * | 2012-10-30 | 2016-08-31 | Kanazawa Medical University | Kit for producing transparentized biological specimen, and method for producing transparentized biological specimen |
| JPWO2014115206A1 (en) * | 2013-01-28 | 2017-01-19 | 国立研究開発法人科学技術振興機構 | Tissue clearing method, tissue clearing reagent, and tissue observation method |
| WO2014115206A1 (en) * | 2013-01-28 | 2014-07-31 | 独立行政法人科学技術振興機構 | Method for rendering tissue transparent, reagent for rendering tissue transparent, and tissue observation method |
| US20160266016A1 (en) | 2013-08-14 | 2016-09-15 | Riken | Composition for preparing biomaterial with excellent light-transmitting property, and use thereof |
| US10267714B2 (en) | 2013-08-14 | 2019-04-23 | Riken | Composition for preparing biomaterial with excellent light-transmitting property, and use thereof |
| US10746981B2 (en) | 2014-05-30 | 2020-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging large intact tissue samples |
| JPWO2016117614A1 (en) * | 2015-01-20 | 2017-10-26 | 国立研究開発法人理化学研究所 | Clarification reagent for biological material, system and use thereof |
| WO2016117614A1 (en) * | 2015-01-20 | 2016-07-28 | 国立研究開発法人理化学研究所 | Biological-specimen transparentizing agent, system, and use therefor |
| WO2017093323A1 (en) | 2015-12-01 | 2017-06-08 | Universität Duisburg-Essen | Non-hazardous optical clearing of biological samples |
| US11254974B2 (en) | 2016-02-10 | 2022-02-22 | The Board Of Trustees Of The Leland Stanford Junior University | RNA fixation and detection in clarity-based hydrogel tissue |
| US12098418B2 (en) | 2016-02-10 | 2024-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | RNA fixation and detection in CLARITY-based hydrogel tissue |
| US10359344B2 (en) | 2017-04-21 | 2019-07-23 | Korea Research Institute Of Chemical Technology | Composition for clearing of biotissue and clarity method for biotissue using thereof |
| US20180306687A1 (en) * | 2017-04-21 | 2018-10-25 | Korea Research Institute Of Chemical Technology | Composition for clearing of biotissue and clarity method for biotissue using thereof |
| US11022528B2 (en) | 2017-04-21 | 2021-06-01 | Korea Research Institute Of Chemical Technology | Composition for biological tissue transparency and method for biological tissue transparency using same |
| US11365213B2 (en) | 2018-02-05 | 2022-06-21 | Korea Research Institute Of Chemical Technology | Composition for clearing spheroids, method for clearing spheroids using same, and kit comprising same |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108061677B (en) | 2021-10-29 |
| CN102859344A (en) | 2013-01-02 |
| JP2013522590A (en) | 2013-06-13 |
| EP2547999A1 (en) | 2013-01-23 |
| US20130045503A1 (en) | 2013-02-21 |
| EP2547999B1 (en) | 2020-12-09 |
| CN108061677A (en) | 2018-05-22 |
| US20210131926A1 (en) | 2021-05-06 |
| EP2547999A4 (en) | 2015-04-22 |
| JP5858435B2 (en) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210131926A1 (en) | Clearing reagent for biological material, and use thereof | |
| US20210131925A1 (en) | Method for making biological material transparent and use thereof | |
| US10444124B2 (en) | Clarifying reagent for biological materials and use thereof | |
| US10267714B2 (en) | Composition for preparing biomaterial with excellent light-transmitting property, and use thereof | |
| US10883903B2 (en) | Method for rendering biological material transparent and processing kit for rendering biological material transparent | |
| US20230213415A1 (en) | Method and System for Imaging and Analysis of a Biological Specimen | |
| JP6228205B2 (en) | Methods and compositions for preparing biological specimens for microanalysis | |
| KR101866249B1 (en) | Composition for clrearing of biotissue and clarity method for biotissue using thereof | |
| US12031891B2 (en) | Tissue sample preparation system | |
| US20220317129A1 (en) | Method for preparing biological material for microscopy analysis | |
| El-Nachef et al. | High-resolution 3D fluorescent imaging of intact tissues | |
| Bonzano et al. | Detecting neuronal differentiation markers in newborn cells of the adult brain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 201180013354.4 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11753531 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2012556745 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011753531 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13583548 Country of ref document: US |